EURL ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2016) by ZUANG Valerie et al.
  
 
Valérie Zuang, David Asturiol Bofill, João Barroso, Susanne Belz, Elisabet Berggren, Camilla 
Bernasconi, Stephanie Bopp, Ann-Charlotte Bostroem, Mounir Bouhifd, Silvia Casati, Sandra Coecke, 
Tom Cole, Raffaella Corvi, Marlies Halder, Tracey Holley, Tomislav Horvat, Annett Janusch-Roi, Aude 
Kienzler, Brigitte Landesmann, Federica Madia, Anne Milcamps, Sharon Munn, Alicia Paini, Taina 
Palosaari, Anna Price, Pilar Prieto, Andrea Richarz, Jutta Triebe, Clemens Wittwehr, Andrew Worth and 
Maurice Whelan 
<Main subtitle, Verdana 10, line spacing 12pt>  
 
EURL ECVAM Status Report on the 
Development, Validation and 
Regulatory Acceptance of Alternative 
Methods and Approaches (2016) 
2016   
 
EUR 28156 EN 
 
 
  
  
This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s 
science and knowledge service. It aims to provide evidence-based scientific support to the European policy-
making process. The scientific output expressed does not imply a policy position of the European Commission. 
Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use 
which might be made of this publication. 
 
Contact information 
Name: Valérie Zuang 
Address: via Enrico Fermi 2749. TP 126 
I-21027 Ispra (VA), Italy 
E-mail: valerie.zuang@ec.europa.eu 
 
 
JRC Science Hub 
https://ec.europa.eu/jrc 
 
JRC103522 
 
EUR 28156 EN 
 
PDF ISBN 978-92-79-63031-6 ISSN 1831-9424 doi: 10.2787/400140 
Print ISBN 978-92-79-63030-9 ISSN 1018-5593 doi: 10.2787/644905 
 
Luxembourg: Publications Office of the European Union, 2016  
 
© European Union, 2016 
 
Reproduction is authorised provided the source is acknowledged. 
 
How to cite: Author(s); title; EUR; doi 
 
All images © European Union 2016,  
 
Status of alternative approaches to animal testing   
Abstract 
Replacement, Reduction and Refinement of animal testing is anchored in EU legislation. Alternative non-animal 
approaches facilitate a shift away from animal testing. Cell-based methods and computational technologies are 
integrated to translate molecular mechanistic understanding of toxicity into safety testing strategies. 
 
  
 
Table of contents 
 
Executive Summary ............................................................................................... 1 
1 Introduction .................................................................................................... 3 
2 Research and Development Activities on Alternative Methods ................................ 3 
2.1 SEURAT-1 ................................................................................................. 3 
2.1.1 Toxicokinetic Modelling and KNIME workflows ......................................... 4 
2.1.2 Evaluation of the SEURAT-1 Read-Across Case Study on β-Olefinic Alcohols 
According to the ECHA Read-Across Assessment Framework (RAAF) ......... 6 
2.2 EU-ToxRisk ................................................................................................ 7 
2.3 Development of a Defined Approach/Predictive Model for Skin Sensitisation 
Prediction ................................................................................................... 7 
2.4 Generation and Use of High Throughput Screening Data in EU Projects ............. 8 
2.5 Fish Toxicity and Bioaccumulation R&D Projects ............................................. 9 
2.5.1 Use of a Fish Cell Line-Based Cytotoxicity Assay for Acute Fish Toxicity 
Testing .............................................................................................. 9 
2.5.2 Development of AOPs for Chronic Fish Toxicity Testing ............................ 9 
2.5.3 Development of a Tiered Testing Strategy for Fish Bioaccumulation Testing 
Based on In vitro Approaches ............................................................... 9 
2.5.4 Threshold of Toxicological Concern in Aquatic Toxicity Assessment .......... 10 
2.5.5 Scientific Options for Avoiding Chronic Fish Testing on the Basis of Existing 
Data and Extrapolation Approaches ..................................................... 10 
2.6 Quality Control of Vaccines ........................................................................ 11 
2.6.1 Launch of the VAC2VAC project .......................................................... 11 
2.6.2 EURL ECVAM Report on Replacement, Reduction and Refinement of Animal 
Testing in the Quality Control of Human Vaccines.................................. 11 
2.7 Reference Lists of Genotoxic and Non-Genotoxic Chemicals ........................... 11 
2.8 Activities within the European Partnership for Alternative Approaches to Animal 
Testing .................................................................................................... 12 
2.8.1 Toxicokinetics - Exposure Prediction tool .............................................. 13 
2.8.2 EPAA Awards/Prizes .......................................................................... 13 
3 Test Method Submissions ............................................................................... 13 
3.1 EDITOX: Assessent of the Risk for Chemicals to Induce Psychiatric Adverse Side 
Effects (Depression and/or Suicide) ............................................................. 14 
3.2 Bioaccessibility Testing (Bioelution) ............................................................ 14 
3.3 Ashland Reconstructed Human Epidermis Skin Irritation Test ......................... 14 
3.4 SkinEthic™ Human Cornea Epithelium (HCE) Eye Irritation Test ..................... 14 
3.5 Sterlab Reconstructed Human Epidermis Skin Irritation Test .......................... 15 
3.6 SENS-IS Skin Sensitisation Test ................................................................. 15 
4 Validation of Alternative Methods ..................................................................... 17 
4.1 Androgen Receptor Transactivation Assay AR-CALUX .................................... 17 
  
 
4.2 Micronucleus Test and Comet assay in Reconstructed Skin Models for Genotoxicity 
Testing .................................................................................................... 17 
4.3 Hen's Egg test for Micronucleus Induction (HET-MN) for Genotoxicity Testing .. 17 
4.4 Ongoing Validation Studies for Vaccine Quality Control – EDQM Biological 
Standardisation Programme ....................................................................... 17 
4.5 Update on the European Union Network for the Validation of Alternative Methods 
(EU NETVAL) ............................................................................................ 18 
4.6 EURL ECVAM Guidance on the Validation of Alternative Methods to Animal Testing 
  ............................................................................................................. 19 
4.7 EURL ECVAM Scientific Advisory Committee Peer Reviews ............................. 19 
4.8 EURL ECVAM Recommendations ................................................................. 20 
5 Promoting the Regulatory Acceptance and use of Alternative Methods and Approaches . 
  ................................................................................................................... 20 
5.1 PARERE (Preliminary Assessment of Regulatory Relevance) and ESTAF (ECVAM 
Stakeholder Forum) Annual Meetings ........................................................... 20 
5.1.1 PARERE Meeting 2015 ....................................................................... 20 
5.1.2 PARERE ESTAF joint meeting 2015 ...................................................... 20 
5.2 Promoting the Regulatory Acceptance in the context of REACH ...................... 21 
5.2.1 Update of REACH Annexes to Reflect Scientific Progress: ....................... 21 
5.2.1.1 Skin Corrosion/Irritation and Serious Eye Damage/Eye Irritation ...... 21 
5.2.1.2 Skin Sensitisation ....................................................................... 21 
5.2.1.3 Acute Systemic Toxicity ............................................................... 22 
5.3 Update of REACH Guidance on Information Requirements and Chemicals Safety 
Assessment ................................................................................................ 22 
5.3.1 Skin sensitisation .............................................................................. 22 
5.3.2 Acute Systemic Toxicity ..................................................................... 23 
5.4 VICH Guidelines on Vaccines: Harmonisation of Criteria for Waiving of Target 
Animal/Laboratory Animal Batch Safety Testing of Vaccines for Veterinary Use . 24 
5.5 Activities in the OECD Task Force on Hazard Assessment .............................. 24 
5.5.1 Update on Guidance Documents on Defined Approaches for Skin 
Sensitisation .................................................................................... 24 
5.5.2 IATA Case Studies Project including the JRC-CosEU ab initio Case Study .. 25 
5.5.3 Combined Exposure to Chemical Mixtures ............................................ 26 
5.6 Activities in the OECD Test Guideline Programme ......................................... 27 
5.6.1 Development of an OECD Test Guideline on In vitro Fish Hepatic Metabolism
  ...................................................................................................... 27 
5.6.2 Update of OECD Guidance Document 23 on Aquatic Toxicity Testing of 
Difficult Substances and Mixtures ........................................................ 28 
5.6.3 Revision of OECD Guidance Document 126 .......................................... 28 
5.6.4 Revision of OECD Test Guideline 203 ................................................... 28 
5.6.5 Critical Assessment of Technical Requirements in OECD Test Guidelines 
using Vertebrate Non-mammalian Species ........................................... 28 
  
 
5.6.6 OECD Validation Studies with Transgenic Fish and Amphibian Models to 
Identify Endocrine Disruptors ............................................................. 29 
5.6.7 OECD Test Guideline on the Human Cell Line Activation Test (h-CLAT) .... 29 
5.6.8 Performance Based Test Guideline on CYP Induction assays ................... 29 
5.6.9 Integrated Approaches to Testing and Assessment of Non-genotoxic 
Carcinogens ..................................................................................... 30 
5.6.10 Integrated Approaches to Testing and Assessment on Eye Irritation/Serious 
Eye Damage ..................................................................................... 30 
5.6.11 Draft OECD Guidance Document on Good In Vitro Method Practices for the 
Development and Implementation of In Vitro Methods for Regulatory Use in 
Human Safety Assessment ................................................................. 31 
5.6.12 OECD Guidance Document on Considerations for Waiving or Bridging of 
Mammalian Acute Toxicity Tests ......................................................... 32 
5.6.13 Proposal for the Deletion of Test Guideline on the Rodent Dominant Lethal 
Test (TG 478) ................................................................................... 32 
5.6.14 Workshop on Developmental Neurotoxicity........................................... 33 
5.7 Contributions to the OECD Adverse Outcome Pathway Development Programme . 
  ............................................................................................................. 33 
5.8 Promoting Regulatory Acceptance in the Frame of EMA: JEG 3Rs ................... 35 
5.9 Activities of EPAA to Promote the Regulatory Acceptance of Alternative Methods .. 
  ............................................................................................................. 35 
5.9.1 Waiving of Two-year Carcinogenicity Studies ........................................ 35 
5.9.2 Acute toxicity ................................................................................... 35 
5.9.3 The Vaccines Consistency Approach .................................................... 36 
5.9.4 Clostridial vaccine project .................................................................. 36 
5.9.5 Human rabies vaccine project ............................................................. 36 
5.9.6 Harmonisation on Biologicals .............................................................. 37 
5.9.7 Optimised Evaluation of Skin Sensitisation ........................................... 37 
5.10 ILSI HESI activities: Framework for Intelligent Non-Animal Alternative Methods 
for Safety Assessment ............................................................................... 37 
5.11 Standard documentation of exposure models – MERLIN-Expo case study CEN 
Workshop Agreement ................................................................................ 38 
5.12 Analysis of Carcinogenicity Testing for Regulatory Purposes in the European Union 
  ......................................................................................................... 38 
5.13 Strategic Aims for Improving Developmental Neurotoxicity (DNT) testing for 
Different Regulatory Purposes using non-animal methods .............................. 38 
6 Dissemination of Information on Alternatives .................................................... 40 
6.1 Second Meeting of European 3Rs Centres .................................................... 40 
6.2 EURL ECVAM Databases ............................................................................ 40 
6.2.1 In vitro methods: DB-ALM—EURL ECVAM’s DataBase service on ALternative 
Methods to animal experimentation ..................................................... 40 
6.2.2 In silico methods: QSAR Model Database ............................................. 41 
  
 
6.2.3 Tracking System for Alternative Test Methods towards Regulatory 
acceptance (TSAR) ............................................................................ 43 
6.3 Information Retrieval Guidance: EURL ECVAM Search Guide .......................... 43 
6.4 Update on the Adverse Outcome Pathway Knowledge Base (AOP-KB) ............. 43 
6.5 AOP Training Activities .............................................................................. 44 
6.6 Update on the EURL ECVAM Genotoxicity and Carcinogenicity Database of Ames 
Positive Chemicals ..................................................................................... 44 
6.7 Update on CheLIST .................................................................................. 45 
6.8 Update on ChemAgora .............................................................................. 45 
6.9 The Endocrine Active Substances Information System (EASIS) ...................... 46 
6.10 Dissemination and training activities of EPAA ........................................... 48 
6.11 European Citizens' Initiative Action 1: Accelerating progress in the Three Rs 
through knowledge sharing ........................................................................ 48 
7 International Cooperation on Alternative Test Methods (ICATM) .......................... 49 
8 EURL ECVAM strategies .................................................................................. 49 
8.1 Follow-up to the EURL ECVAM Strategy for Achieving 3Rs Impact in the 
Assessment of Toxicokinetics and Systemic Toxicity ...................................... 49 
8.2 Implementing the EURL ECVAM Strategy to Avoid and Reduce Animal use in 
Genotoxicity Testing .................................................................................. 50 
9 Conclusions .................................................................................................. 51 
Annex I – Summary status of the adoption of Test Guidelines based on alternative 
methods in the OECD TG programme (2012-2016).................................................. 52 
Annex II – ICATM Alternative Test Methods Validation and Status of Regulatory 
Acceptance ......................................................................................................... 58 
References ......................................................................................................... 72 
List of figures ...................................................................................................... 81 
List of tables ....................................................................................................... 82 
 
 1 
 
Executive Summary 
Policy context 
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL 
ECVAM) is legally anchored in Directive 2010/63/EU on the protection of animals used 
for scientific purposes1 which defines its duties (Article 48 and Annex VII). The Directive 
mandates the application of scientifically valid alternative approaches and establishes 
mechanisms to speed up their development, validation and uptake. Other pieces of EU 
legislation such as the Cosmetics Regulation2 and the REACH Regulation3 foresee the 
increased use of alternative methods that either Replace, Reduce or Refine (the "Three 
Rs") animal testing. Thus the Three Rs are firmly anchored in EU legislation.  
This EURL ECVAM status report provides an update on the development, validation and 
regulatory acceptance and use of alternative approaches and their dissemination since 
the last report published in September 2015. It informs EURL ECVAM stakeholders and 
the public on ongoing activities in the field and provides input to the annual Commission 
report on alternatives prepared in the framework of the Cosmetics Regulation and to the 
review of Directive 2010/63/EC. The report is also relevant to the European Citizen's 
initiative (ECI) "Stop Vivisection"4 that calls for a regulatory framework that shifts away 
from animal experimentation and makes compulsory the use, in biomedical and 
toxicological research, of data derived from alternative methods that are directly 
relevant for the human species. 
Key conclusions 
The current research and development activities in the field of alternatives 
predominantly focus on the integration of a variety of testing and non-testing methods 
such as in vitro technologies, bioinformatics and computational toxicology into so-called 
Integrated Approaches to Testing and Assessment (IATA). Ideally such IATA are based 
on Adverse Outcome Pathways (AOP), a mechanistic knowledge framework that 
describes a logical sequence of causally linked events at different levels of biological 
organisation, which follows exposure to a chemical and leads to an adverse health effect 
in humans or wildlife. 
The ultimate goal of these activities is to deliver reliable, animal-free hazard and risk 
assessments of chemicals.  
Discussions in various stakeholder and regulatory fora revealed that independent 
scientific and purpose-driven validation remains crucial for the regulatory use and wider 
adoption of alternative approaches.    
In the future however, validation efforts may have to focus on defining and evaluating 
standards for classes of methods to be used within defined approaches to testing and 
assessment, rather than only on the validation of individual methods.  
Main findings 
For complex endpoints, the lack of suitable and mechanistically based methods and their 
optimal integration in regulatory testing frameworks remains a challenge. Therefore EU-
funded research projects continue in this area.  
For the quality control of vaccines, an area which consumes a considerable amount of 
animals, a number of recently launched research projects aim to provide data to support 
                                           
1  Directive 2010/63/EU OJ L276, 20.10.2010, p.33-79 http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:32010L0063   
2 https://ec.europa.eu/growth/sectors/cosmetics/legislation_en 
3 https://echa.europa.eu/regulations/reach/legislation 
4 http://ec.europa.eu/citizens-initiative/public/initiatives/successful/details/2012/000007 
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the consistency approach for routine batch quality control, and safety and efficacy 
testing of established vaccines for human and veterinary use.  
With regard to validation and regulatory acceptance, advanced areas such as local 
toxicities and genotoxicity are covered with alternative methods and approaches. In the 
area of skin sensitisation progress has been made in the development, validation and 
regulatory adoption of various alternative approaches. Recent efforts focused on the 
development of defined approaches to testing and assessment using data generated with 
these methods.  
IATAs are also being developed for non-genotoxic carcinogens and for serious eye 
damage/eye irritation. Complementary IATA case studies support the use of alternative 
methods within IATA by developing guidance and tools. EURL ECVAM regularly engages 
with regulators (through PARERE 5 ), stakeholders (through the ECVAM Stakeholder 
Forum ESTAF6) and validation laboratories (through EU-NETVAL7) as well as with its 
international partners (e.g. ICATM 8 , OECD 9  and USEPA 10 ) to better understand the 
different requirements and to find global solutions.  
Related and future JRC work 
Three Rs knowledge sharing opportunities are being investigated with the aim to explore 
how sharing of knowhow and access to resources could be enhanced to accelerate 
overall progress in the Three Rs. This is explored in every domain where animals are 
used for a scientific purpose, be it for basic biological research, toxicological testing, or 
for training and education purposes. 
Quick guide 
Alternative non-animal methods do not use live animals for safety, efficacy and quality 
control testing of chemicals and products. They include in vitro (test tube) test methods 
and models based on human cell and tissue cultures, computer models and simulations 
(also called in silico methods) as well as stem cell and genetic testing methods.  
The Three Rs concept is the requirement to Replace, Reduce and Refine the use of 
animals wherever possible. This means that animal studies should be either replaced by 
methods not involving animals, or adapted to reduce the number of animals needed, or 
refined so as to minimise pain, suffering or distress experienced by the animal, or to 
increase their welfare. The Three Rs are firmly anchored in all EU legislations. 
IATA are frameworks used for hazard identification, hazard characterisation and/or 
safety assessment of a chemical or group of chemicals, which strategically integrates 
and weights all relevant existing data and guide the targeted generation of new data 
where required to inform regulatory decision-making regarding potential hazard and/or 
risk.  
 
                                           
5 PARERE Network (Preliminary Assessment of REgulatory RElevance) established under 
Article 47(5) of Directive 2010/63/EU   
6 https://eurl-ecvam.jrc.ec.europa.eu/about-ecvam/scientific-advice-stakeholders-
networks/estaf-ecvam-stakeholder-forum 
7  European Union Network for the Validation of Alternative Methods (EU NETVAL) 
https://eurl-ecvam.jrc.ec.europa.eu/eu-netval established under Article 47(2) of 
Directive 2010/63/EU 
8  The International Cooperation on Alternative Test Methods (ICATM) includes 
governmental organisations from the EU, US, Japan, Canada, South Korea, Brazil and 
China. ICATM partners are working together to promote enhanced international 
cooperation and coordination on the scientific development, validation and regulatory 
use of alternative approaches  
9 Organisation for Economic Cooperation and Development (OECD)  
10 United States Environmental Protection Agency (USEPA) 
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1 Introduction  
The EURL ECVAM status report provides an update on the progress made in the 
development, validation and regulatory acceptance and use of alternative methods and 
approaches and their dissemination since the last report published in September 2015. It 
is informing on ongoing research and development activities, validation studies, EURL 
ECVAM Scientific Advisory Committee (ESAC) scientific peer reviews, EURL ECVAM 
Recommendations, EURL ECVAM strategies as well as on activities which promote the 
regulatory acceptance and use of alternative approaches and their dissemination. 
It describes primarily, but not exclusively, all the activities that EURL ECVAM has 
undertaken or has been involved in since the publication of the last report and covers 
the period October 2015 to September 2016. 
It is intended to inform EURL ECVAM stakeholders and any interested parties on on-
going activities in the field of alternative approaches and serves multiple purposes. This 
includes providing input to the annual Commission report on the progress made in the 
development, validation and regulatory acceptance of alternative methods/approaches 
prepared in the framework of Regulation 1223/2009 on cosmetic products and to the 
review of Directive 2010/63/EC on the protection of animals used for scientific purposes. 
 
2 Research and Development Activities on Alternative 
Methods 
2.1 SEURAT-1  
SEURAT-1, the cluster of FP7 projects on safety assessment of chemicals replacing 
animal testing for repeated dose toxicity, was a private-public co-sponsored initiative 
equally shared between Cosmetics Europe and the European Commission (EC). The five 
research projects finalised their activities at the end of 2015, and the final results were 
presented at the SEURAT-1 symposium on the 4th December 2015 in Brussels. It was 
recognised that the initiative had successfully addressed the overall goal on safety 
assessment for regulatory use in a series of case studies. This was also demonstrated 
through the application of the ECHA read-across assessment framework (RAAF; see 
2.1.2) to two of the SEURAT-1 case studies that were presented and discussed at the 
Topical Scientific Workshop at ECHA, 19th – 20th April 2016. In addition, SEURAT-1 
provided an extremely rich toolbox developed by the different projects with a multitude 
of expertise resulting in a large variety of alternative methods, techniques and compiled 
information, which is available through ToxBank 11 , DB-ALM 12 , COSMOS Space 13 , 
COSMOS KNIME WebPortal 14  and COSMOS Database 15  (being updated beyond the 
project and including an extended TTC dataset and a TTC Workflow). More information 
can be found on the SEURAT-1 public web-page16.  
COACH, the coordination action, is continuing its work in 2016, mainly to disseminate 
the SEURAT-1 achievements, and also to finalise some of the case study activities. A 
final workshop is planned at the JRC, Ispra, in collaboration with EURL ECVAM and the 
H2020 project, EU-ToxRisk (see 2.2), to further explore the current status of regulatory 
                                           
11 http://toxbank.net/  
12 EURL ECVAM's Database on Alternative Methods: 
 https://ecvam dbalm.jrc.ec.europa.eu/  
13 http://cosmosspace.cosmostox.eu/   
14 https://knimewebportal.cosmostox.eu/ 
15 https://cosmosdb.eu/cosmosdb.v2/ 
16 http://www.seurat-1.eu/  
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use of alternative approaches in toxicology for the safety assessments of chemicals and 
possibilities for further progress. 
2.1.1 Toxicokinetic Modelling and KNIME workflows 
During the final year (2015) of the five-year COSMOS project17, nine physiologically-
based kinetic (PBK) models coded in R language were implemented into Konstanz 
Information Miner (KNIME) workflows (see  
                                           
17  http://www.cosmostox.eu/ 
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Table 2.1). A PBK model is a mathematical model for predicting the absorption, 
distribution, metabolism and excretion (ADME) of a compound in humans and other 
animal species. The model can be used to simulate relevant time profiles concentration 
of selected chemicals and its metabolites. PBK models are used to predict in vivo 
toxicokinetics (e.g. time-course of blood or tissue concentrations of a chemical) based on 
in vitro measurements of the underlying ADME processes (in vitro to in vivo 
extrapolation; IVIVE), as well as to extrapolate existing animal blood time-courses of a 
chemical for one exposure route to another exposure route (route-to-route 
extrapolation; RtR), e.g. oral-to-dermal extrapolation. Route-to-route extrapolation is a 
common part of human risk assessment. Data from oral animal toxicity studies are used 
to assess the safety of specific exposure scenarios. PBK modelling approaches can be 
used to predict animal as well as human internal exposure dose metric, called "Margin of 
Internal Exposure (MOIE)" (Bessems et al., submitted). 
In addition, the Virtual Cell Based Assay (VCBA), developed by the JRC to model the fate 
and toxicity of chemicals in in vitro assays, was made publicly accessible by 
implementation as web-accessible KNIME workflows. Following a multi-scale modelling 
approach, PBK models were coupled with VCBA models to enable realistic estimates of in 
vivo effects from in vitro toxicity data. This work will be published in a special issue of 
Toxicology in vitro entitled The Virtual Cell Based Assay (Zaldivar et al., in press, 
Graepel et al., submitted). The description of the PBK and bioaccumulation models and 
VCBA were introduced in DB-ALM18 (see 6.2.1) as method summaries/protocols nos. 
161, 162 and 163. A summary of the overall COSMOS achievements in the area of 
toxicokinetic modelling was published in Toxicology (Bois et al., 2016). 
The above-mentioned computational workflows (among others) can be accessed via the 
KNIME WebPortal19, following registration through COSMOS Space20. COSMOS Space is a 
platform for the sharing of predictive toxicology resources (e.g. data sets, models, 
workflows, documentation). The workflows were presented at the SEURAT-1 Stakeholder 
event held in Brussels in December 2015. 
The EURO-mix consortium21 is evaluating the potential use of the VCBA and the PBK 
models developed within COSMOS to refine in vitro testing and achieve point of 
departure for risk assessment. 
  
                                           
18  https://ecvam-dbalm.jrc.ec.europa.eu/  
19  http://knimewebportal.cosmostox.eu 
20 http://cosmosspace.cosmostox.eu 
21 http://www.euromixproject.eu/ 
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Table 2.1 List of the biokinetics workflows developed in COSMOS and available in the COSMOS KNIME 
WebPortal at http://knimewebportal.cosmostox.eu. 
Type Chemical Exposure Species Output   
PBK Caffeine Oral, Dermal Human, rat Time kinetics 
PBK Coumarin Oral, Dermal Human, rat Time kinetics 
PBK 
Ethanol 
Oral, 
Inhalation Human, rat Time kinetics 
PBK Estragole Oral, Dermal Human Time kinetics 
PBK Hydroquinone Oral, Dermal Human, rat Time kinetics 
PBK Isopropanol Oral, Dermal Human, rat Time kinetics 
PBK Methyliodide Oral, Dermal Human, rat Time kinetics 
PBK Nicotine Intra-venous Human Time kinetics 
PBK Styrene Inhalation Human Time kinetics 
QIVIVE Caffeine Oral, Dermal Human Time-dose kinetics 
QIVIVE Coumarin Oral, Dermal Human Time-dose kinetics 
QIVIVE Estragole Oral, Dermal Human Time-dose kinetics 
Type Chemical Exposure Cell Type Output  
VCBA 30 chemicals in vitro 
HepaRG, 3T3 
Balbc, HepG2, 
A549 
Time-dose kinetics/dynamics 
 
2.1.2 Evaluation of the SEURAT-1 Read-Across Case Study on β-Olefinic 
Alcohols According to the ECHA Read-Across Assessment 
Framework (RAAF)  
The chemical properties and toxicity of a target substance with no data can be inferred 
from substances with known properties/existing data by read-across, based on the 
grouping of similar substances. This approach is increasingly used for filling data gaps 
for regulatory submissions such as REACH dossiers. The European Chemicals Agency 
(ECHA) has set up the ECHA Read-Across Assessment Framework (RAAF) to provide 
guidance for a structured analysis of these read-across submissions and assessment of 
the justifications. The RAAF and its Assessment Elements were used to systematically 
analyse the read-across argumentation and the contribution of New Approach 
Methodologies (NAM) - defined as including any in silico, in chemico or in vitro 
techniques supporting the substance evaluation - to reduce uncertainties in selected 
case studies, including two from the SEURAT-1 Initiative (Berggren et al., 2015). The 
analysis of the β-olefinic alcohols case study led by JRC highlighted the major sources of 
uncertainty, in particular the need for more (quantitative) kinetic and metabolism 
pathway data, demonstrated the support by NAM of the read-across hypothesis, and 
showed further opportunities to use NAM, e.g. through targeted testing (Richarz, 2016). 
The study was presented and discussed at the ECHA Topical Scientific Workshop on New 
 7 
 
Approach Methodologies in Regulatory Science, held on 19-20 April 2016 in Helsinki, 
Finland22 (ECHA, 2016b). 
2.2 EU-ToxRisk  
EU-ToxRisk is a Horizon2020 consortium of 39 partners funded by the European 
Commission to work on the integration of in vitro non-animal methods and in silico 
computational technologies to translate molecular mechanistic understanding of toxicity 
into safety testing strategies 23 . The ultimate goal is to deliver reliable, animal-free 
hazard and risk assessment of chemicals. The project started with a meeting in Egmond 
aan Zee on 13th to 15th January 201624 and is building further on the activities started by 
the SEURAT-1 initiative. EU-ToxRisk continues to evaluate methodologies for repeated 
dose toxicity, but also for developmental and reproductive toxicity. The project is built 
up around different case studies, to better capture possibilities and shortcomings in 
safety assessment applications. A first summer school and a second consortium meeting 
took place in Egmond aan Zee in the last week of June 2016. In September 2016, EU-
ToxRisk organised a meeting with the US Tox2125 to proceed with a fruitful US-European 
collaboration on a more efficient toxicity testing applying new approaches that was 
started with SEURAT-1. 
2.3 Development of a Defined Approach/Predictive Model for Skin 
Sensitisation Prediction  
Within the framework of the recently developed OECD guidance documents on the 
reporting of defined approaches within Integrated Approaches to Testing and 
Assessment (IATA)(OECD 2016a; OECD 2016b), EURL ECVAM has developed a case 
study on the prediction of skin sensitisation.  
In order to develop the defined approach, a dataset with high quality data from the 
direct peptide reactivity assay (DPRA) (Gerberick et al., 2004; EURL ECVAM 2013), 
KeratinoSensTM (Natsch and Emter 2008; Emter et al., 2010; EURL ECVAM 2014), and 
the human cell-line activation test (h-CLAT) (Ashikaga et al., 2006; Sakaguchi et al., 
2006; EURL ECVAM 2015) was compiled and curated in collaboration with the test 
method developers. The dataset comprises 269 chemicals with data generated with one 
or more of the test methods and complemented with molecular descriptors and 
predictions from various in silico tools (i.e. OECD QSAR ToolBox, Derek Nexus, Toxtree, 
Dragon, Vega, TIMES, and ADMET Predictor) and LLNA data.  
The modelling exercise consisted of finding the best combination of descriptors to predict 
skin sensitisation hazard (sensitiser/non-sensitiser) using the LLNA results as reference 
classifications. In order to do so, an algorithm (C4.5) was used that combines the best 
descriptors into decision trees, which are simple and easily interpretable predictive 
models based on a sequence of descriptors (properties of each chemical) and their 
threshold values. Therefore, the algorithm determines the optimal descriptors, order and 
thresholds for predicting skin sensitisation potential for a list of chemicals and 
corresponding descriptors/properties.  
Different models were built for different subsets of the original dataset depending on the 
availability of in chemico/in vitro data. It was found that skin sensitisation hazard was 
                                           
22 https://echa.europa.eu/view-article/-/journal_content/title/topical-scientific-
workshop-new-approach-methodologies-in-regulatory-science; presentation: 
https://echa.europa.eu/documents/10162/22301701/presentation_bos_richarz_en.pdf; 
summary of the discussion: 
https://echa.europa.eu/documents/10162/22301701/bos_2_en.pdf 
23  http://cordis.europa.eu/project/rcn/198787_en.html  
24  https://www.eurtd.com/eu-toxrisk/2016/kick-off-meeting/  
25  http://tox21.org/  
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best predicted by decision trees based on molecular descriptors and in silico predictions, 
and that the most discriminating descriptor was the amount of protein-hapten adduct 
formation provided by TIMES-SS (Dimitrov et al., 2005). 
In order to provide a defined approach with the lowest reasonable number of false 
negative predictions (highest sensitivity), the two decision trees with the highest 
accuracy and highest specificity were combined into a final consensus model. Thus, the 
defined approach (Asturiol et al., 2016) consists of a consensus of two classification 
trees that are both based on descriptors that account for protein reactivity and structural 
features. The defined approach has an accuracy of 0.93, sensitivity of 0.98, and 
specificity of 0.85 for 269 chemicals. In addition, the defined approach provides a 
measure of confidence (very high, high, low, very low) associated with each prediction. 
The dataset and model will be made publicly available on the EURL ECVAM website. 
2.4 Generation and Use of High Throughput Screening Data in EU 
Projects 
High throughput screening (HTS) data has been used in several EU projects such as the 
NanoMILE Project which is a large collaborative project under the European 
Commission's 7th Framework Programme. The project aims to establish a fundamental 
understanding of the mechanisms of nanomaterial interactions with living systems and 
the environment across the entire life cycle of nanomaterials and in a wide range of 
target species. Due to the diversity of manufactured nanomaterials (MNM) regarding 
chemical composition, surface modification, size, and other parameters the number of 
materials to be tested for safe application is steadily increasing. For effective safety 
screening of numerous MNMs it is necessary to speed up the testing by using in vitro 
test systems and applying High Throughput/ High Content methods.  
The HTS facility at EURL ECVAM laboratory was used to establish a screening platform 
based on High Throughput /High Content Imaging techniques in two stages: 
a) Screening for the most relevant MNMs and endpoints (using both classical and novel 
biomarkers) and, 
b) Further validating the utility of novel mechanistic pathway specific biomarkers and 
developing future test methods based on high throughput profiling of MNMs. 
The materials tested were selected from a library of different MNMs of different sizes, 
different chemistry and coatings/modifications. To date, more than 100 MNMs from the 
NanoMILE library have been screened at the EURL ECVAM HTS facility. Since the liver is 
a major target organ for MNM toxicity, a human hepatoma cell line, HepaRG, was used 
as in vitro cell model. Cells cultured in vitro represent ideal high-throughput and ethically 
acceptable systems to assess toxicity.  
Similarly, data were generated at the HTS facility for the SEURAT-1 project (see 2.1). 
The case study "Mode of Action (MoA)-based Classification Model for Repeated Dose 
Liver Toxicity" was developed to compare the performances of several classification 
models for hepatotoxicity, which is mainly related to three major liver adverse outcomes 
associated with repeated dose exposure: cholestasis, fibrosis and steatosis. HepaRG cells 
were exposed to 90 selected reference compounds (75% known hepatotoxicants and 
25% known non-hepatotoxicants), including cosmetics, pharmaceuticals, pesticides and 
environmental chemicals. The read-out of the in vitro endpoints was performed using 
high content screening. In this automated multiparametric analysis the following key 
events were assessed: mitochondrial damage, reactive oxygen species formation 
(indicator of oxidative stress), formation of neutral lipid droplets (indicator of chemically 
induced steatosis), apoptosis and cell viability. Concentration-response data for each of 
these parameters are generated to determine the lowest concentration at which the 
effect is observed. 
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2.5 Fish Toxicity and Bioaccumulation R&D Projects   
Several R&D projects related to fish toxicity and bioaccumulation, which are of specific 
interest to EURL ECVAM, are described below.  
2.5.1 Use of a Fish Cell Line-Based Cytotoxicity Assay for Acute Fish 
Toxicity Testing 
As a follow-up to the CEllSens 26  project (Tanneberger et al., 2013), a ring trial 
evaluating the transferability and within-laboratory reproducibility of the RTgill-W1 
(rainbow trout gill cell line) cytotoxicity assay has been organised by the Swiss Federal 
Institute of Aquatic Science and Technology (EAWAG; K. Schirmer; CEFIC Long-Range 
Research Initiative [LRI] project ECO8.3-NC3Rs-EAWAG27). A paper on the outcome of 
the ring trial is in preparation.  
In addition, the method had been submitted to EURL ECVAM in early 2014 and the test 
submitter had been invited to provide a full submission (see 3.1 of EURL ECVAM Status 
report, Zuang V. et al., 2015).  
An ISO guideline "Water quality - Determination of acute toxicity of chemicals and water 
samples to a fish gill cell-line (RT gill-W1)" is in preparation. 
2.5.2 Development of AOPs for Chronic Fish Toxicity Testing  
Several research groups are working on the identification and description of potential 
AOPs relevant to chronic fish toxicity, which is currently assessed with fish early life-
stage (FELS) test (OECD TG 210, 2013a). A CEFIC LRI-funded project (LRI-ECO20-UA28) 
aimed at mapping FELS-relevant AOPs and developing an in vitro toolbox and zebrafish 
embryo based assays to test for AOP-specific events and responses predictive for FELS 
chronic toxicity. A summary of the outcome of the project is available on the CEFIC LRI 
website29. The overall objective of the recently started follow-up project LRI-ECO20.230 
is the validation of the assays developed for the two most promising AOPs, the thyroid 
AOP and the narcosis AOP. It is planned to test around 25 chemicals in vitro and to 
predict, based on the assay results, acute and chronic toxicity. The consortium further 
plans to perform, for a subset of the chemicals tested, acute (fish embryo toxicity test) 
and chronic fish toxicity tests (OECD TG 210, 2013a) to validate the predictions derived 
with the in vitro assays.  
2.5.3 Development of a Tiered Testing Strategy for Fish Bioaccumulation 
Testing Based on in vitro Approaches  
This new CEFIC LRI-funded project (LRI-ECO34)31 combines various in vitro approaches 
using fish cell lines to estimate chemical uptake and biotransformation with toxicokinetic 
and quantitative structure activity relationship models to develop a tiered approach for 
the assessment of the bioaccumulation potential of chemicals. 
                                           
26 http://cefic-lri.org/projects/eco8-development-of-a-strategy-to-predict-acute-fish-
lethality-using-fish-cell-lines-and-fish-embryos/ 
27 http://cefic-lri.org/projects/eco8-3-nc3rs-eawag-round-robin-test-of-the-rtgill-w1-cell-
line-assay-to-study-its-robustness-in-establishment-and-inter-laboratory-comparability/ 
28 http://cefic-lri.org/projects/lri-eco20-ua-development-of-an-alternative-testing-
strategy-for-the-fish-early-life-stage-test-for-predicting-chronic-toxicity/ 
29 http://cefic-lri.org/wp-content/uploads/2014/03/LRI-ECO20-UA_Executive-summary_ 
March2016.pdf 
30 http://cefic-lri.org/projects/eco20-2-development-of-an-alternative-testing-strategy-
for-the-fish-early-life-stage-test-for-predicting-chronic-toxicity-assay-validation/ 
31 http://cefic-lri.org/projects/eco34-a-tiered-testing-strategy-for-rapid-estimation-of-
bioaccumulation-by-a-combined-modelling-in-vitro-testing-approach/ 
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2.5.4 Threshold of Toxicological Concern in Aquatic Toxicity Assessment 
The Threshold of Toxicological Concern (TTC) approach is based on the premise that 
there is a general exposure limit for chemicals below which no significant risk to human 
health or the environment is expected. It is well established for assessing human safety 
of substances present in low levels in food and feed (Kroes et al., 2004; EFSA Scientific 
Committee, 2012).  
The potential usefulness of the TTC approach for various applications in environmental 
toxicity and risk assessment has been explored and reported by several groups (for 
example by: (de Wolf et al., 2005; Gross et al., 2010; Williams et al., 2011; Gutsell et 
al., 2015)).  
An international collaboration under the ILSI HESI has been established to address 
challenges relating to the development and application of useful ecotoxicological 
threshold of concern (eco-TTC) concepts. Belanger et al., 2015, outline the major 
challenges of data collection, quality control, data characterisation and analysis. EURL 
ECVAM is contributing to this initiative.  
2.5.5 Scientific Options for Avoiding Chronic Fish Testing on the Basis of 
Existing Data and Extrapolation Approaches 
The assessment of aquatic toxicity is an important component of the environmental 
hazard and risk assessment of all types of chemicals, and is therefore included in several 
pieces of EU chemicals legislation. Aquatic toxicity refers to the effects of chemicals on 
organisms living in the water and is usually determined by testing on organisms 
representing the three trophic levels, i.e. plants (or algae), invertebrates (crustaceans 
such as Daphnia spp.) and vertebrates (fish). Whereas acute aquatic toxicity testing is a 
basic requirement in most pieces of EU chemicals legislation, chronic aquatic toxicity 
testing may be required on a case by case basis, for example when the outcome of the 
acute testing indicates a risk, or when a long-term exposure to the chemical is expected. 
In the light of the EU Directive 2010/63 on the protection of animals used for scientific 
purposes and the EURL ECVAM strategy to replace, reduce and refine the use of fish in 
aquatic toxicity and bioaccumulation testing 32 , EURL ECVAM explored whether 
interspecies extrapolations and acute-to-chronic relationships could be used to 
scientifically support the waiving of chronic fish tests. For this purpose, acute and 
chronic toxicity data for Daphnia and fish were extracted from various databases and 
analysed to identify possible relationships taking into consideration different mode of 
actions.  
The results of this analysis indicate that several types of aquatic toxicity data can be 
used to assess the potential for chronic fish toxicity. In particular, interspecies 
extrapolations based on invertebrate (Daphnia) data, and acute-to-chronic 
extrapolations from existing acute fish toxicity data, are recommended as a means of 
deriving information on chronic fish toxicity without the need to perform additional fish 
tests. 
EURL ECVAM published the report on Scientific options for avoiding chronic fish testing 
on the basis of existing data and extrapolation approaches in May 2016 (Kienzler et al., 
2016a).  
                                           
32 https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-fish 
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2.6 Quality Control of Vaccines  
2.6.1 Launch of the VAC2VAC project  
The new VAC2VAC project33 - "Vaccine batch to vaccine batch comparison by consistency 
testing" – officially launched on 1st March 2016, brings together 20 public and private 
partners including the JRC represented by EURL ECVAM. 
VAC2VAC is funded under the Innovative Medicines Initiative 2 (IMI 2), a Joint 
Undertaking of the European Union’s Horizon 2020 research and innovation programme 
and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The 
project will provide data to support the consistency approach for quality control of 
established vaccines for human and veterinary use. The consistency approach moves 
away from the current focus on final product control often relying on animal testing. In 
the light of this, VAC2VAC partners will develop, optimise and evaluate non-animal 
methods, e.g. physicochemical and immunochemical methods, cell-based and other 
assays for routine batch quality, safety and efficacy testing of vaccines, in collaboration 
and consultation with regulatory agencies.  
EURL ECVAM is participating in the project as leader of the work package related to 
validation, and will also support project activities related to international dissemination, 
harmonisation and regulatory acceptance of consistency approaches.  
Over the last decade EURL ECVAM, in collaboration with international experts and EPAA, 
organised several workshops on the use of the consistency approach for the quality 
control of vaccines (Metz et al., 2007; Hendriksen et al., 2008; De Mattia et al., 2011) 
and supported the EPAA Vaccines Consistency Project (De Mattia et al., 2015; see also 
5.9.3).  
2.6.2 EURL ECVAM Report on Replacement, Reduction and Refinement of 
Animal Testing in the Quality Control of Human Vaccines 
EURL ECVAM released in 2016 a report to inform its stakeholders on ongoing activities in 
development and validation of Three Rs methods for the quality control of vaccines for 
human use (Halder, 2015). The focus of the report is on methods for lot release testing 
(e.g. safety, pyrogenicity, potency) and projects related to the implementation of the 
consistency approach to established vaccines such as diphtheria, tetanus, pertussis and 
rabies vaccines.  
Vaccines are recognised as a highly cost effective tool for preventing infectious diseases. 
They are derived from biological sources and due to the complexity of composition and 
heterogeneity of products, vaccine lots undergo legally required quality control before 
they are released. Traditionally, laboratory animals have played an important role in 
quality control of vaccines and still, many laboratory animals are used in Europe for this 
purpose. Over the last decades, Three Rs methods to classical animal tests have been 
developed by control authorities, academia and vaccine manufacturers.  
As the report shows, progress has been achieved and new approaches to quality control 
such as the consistency approach have the potential to further reduce animal use. 
2.7 Reference Lists of Genotoxic and Non-Genotoxic Chemicals  
Reference chemical selection is a key step in the development, optimisation and 
validation of alternative test methods. A first reference list, of genotoxic and non-
genotoxic chemicals, published in 2008 (Kirkland et al., 2008), has become an 
internationally recognised resource for scientists and has been used for a variety of 
purposes, including the development of new assays, the optimisation of existing test 
                                           
33 www.vac2vac.eu 
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protocols, the implementation of automated high throughput assays, and the design of 
validation studies. In addition, the reference list has proven invaluable in the attempt to 
reduce misleading positive results obtained from some in vitro methods. 
In light of newly available data, it was considered appropriate to update this list of 
genotoxic and non-genotoxic chemicals recommended for assessing the performance of 
new or improved in vitro genotoxicity test methods. The list was updated to fit the 
following different sets of characteristics (Kirkland et al., 2016):  
Group 1: Chemicals that should be detected as positive in in vitro mammalian cell 
genotoxicity tests. Chemicals in this group are all in vivo genotoxins at one or more 
endpoints, either due to DNA-reactive or non DNA-reactive mechanisms.  
Group 2: Chemicals that should give negative results in in vitro mammalian cell 
genotoxicity tests. Chemicals in this group are usually negative in vivo and non-
DNA-reactive. They are either non-carcinogenic or rodent carcinogens with a non-
mutagenic mode of action.  
Group 3: Chemicals that should give negative results in in vitro mammalian cell 
genotoxicity tests, but have been reported to induce gene mutations in mouse 
lymphoma cells, chromosomal aberrations or micronuclei, often at high 
concentrations or at high levels of cytotoxicity. Chemicals in this group are generally 
negative in vivo and negative in the Ames test. They are either non-carcinogenic or 
rodent carcinogens with an accepted non-mutagenic mode of action. This group 
contains comments as to any conditions that can be identified under which 
misleading positive results are likely to occur. 
These recommended lists, which now contain a total of 69 chemicals of different 
structural classes and modes of action and the supporting data are expected to make an 
important contribution to the development and acceptance of new and refined in vitro 
genotoxicity test methods with improved predictivity and technical performance. 
2.8 Activities within the European Partnership for Alternative 
Approaches to Animal Testing  
The European Partnership for Alternative Approaches to Animal Testing (EPAA) is a 
public-private collaboration between the European Commission, European trade 
associations and companies from seven business sectors.  
In 2015 the EPAA celebrated its 10th anniversary and launched a new five-year Action 
Programme (2016 - 2020)34 at its Annual Conference in December 2015, whose report is 
available online35. 
The partners are committed to pooling knowledge and resources to accelerate the 
development, validation and acceptance of alternative approaches to animal use in 
regulatory testing. The overall aim is the replacement, reduction and refinement (Three 
Rs) of animal use in regulatory testing. JRC, represented by EURL ECVAM, is one of the 
Commission services that are members of the EPAA. 
EPAA recently concluded one research project on toxicokinetics (see 2.8.1), while other 
activities have focussed on regulatory acceptance (see 5.9), (pre)validation (see 5.9.3, 
5.9.4 and 5.9.5) and training & dissemination (see 6.10). 
                                           
34 See: https://circabc.europa.eu/sd/a/1ccf4a54-b374-4ab1-bf6c-b95200f62aab/action-
programme-2016-2020.pdf 
 
35 See: https://circabc.europa.eu/sd/a/385c4f37-e8d3-4b82-8652-
47a64513b58b/EPAA_AC2015_Report.pdf 
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2.8.1 Toxicokinetics - Exposure Prediction tool 
Starting in 2014, an EPAA project was carried out for the development of an exposure 
prediction tool converting in vivo to in vitro exposure data and vice-versa. The project 
was completed mid-2016 and aimed at (i) the further development of the existing web-
based Model Equation Generator MEGen36 established for the generation and analysis of 
physiologically based kinetic (PBK) models and (ii) the generation of a prototype of a 
free-to-use, web-based, open-source tool ("RVis") that would enable in vitro/in vivo 
exposure predictions. 
The EPAA project developed a prototype (beta-release) of the RVis application which is 
currently being tested by EPAA partners and other experts. EURL ECVAM participated in 
the technical advisory team to the project and is involved in the group of experts testing 
the application prior to enter a second development phase.  The latter will be part of a 
future project funded by Cefic's programme LRI37 and will result in the provision of the 
final open-access version of RVis to be made freely available online. The final tool will 
also be downloadable to the user's PC in order to avoid the need for uploading 
proprietary information to the web and thus assuring the confidentiality of the user's 
data. 
2.8.2 EPAA Awards/Prizes 
The EPAA Awards are granted to young scientists (Three Rs Science Prize) or laboratory 
technicians and animal caretakers (Three Rs Technician Prize), respectively, whose work 
has brought an outstanding contribution to the development and implementation of 
alternatives to animal testing. Both, the Science and the Laboratory technician prize are 
awarded alternating every other year. 
In 2015, the EPAA granted the Three Rs Technicians Prize to a laboratory supervisor, 
working for a company in Germany, for her work in developing and establishing a multi-
organ chip for the co-culture of organ equivalents for long-term (up to 28 days) 
substance testing. The chip allows flexible arrangements of 2 to 10 different organ 
equivalents and a connection to two different circuits reflecting the circulatory and 
excretory systems. The Prize winner presented her work to the participants of the EPAA 
Annual Conference in December 2015. 
 
3 Test Method Submissions 
Since the last EURL ECVAM status report published in September 2015, six new test 
submissions were evaluated by EURL ECVAM, three pre-submissions (EDITOX, Bioelution 
and Ashland RHE SIT) and three full submissions (SkinEthic HCE EIT, Sterlab RHE SIT 
and SENS-IS). Moreover, EURL ECVAM discussed the results of the PARERE consultation 
on a test method for teratogenicity testing (devTOXqP, see 5.1) and reviewed the 
validation project plan of the Genomic Allergen Detection (GARD) method (see 3.7.1 of 
EURL ECVAM status report 2015, Zuang et al., 2015). A database that tracks the status 
of a test method from its submission through its final adoption into a regulatory 
framework (EU, OECD and related standards) is currently under development (TSAR, see 
6.2.3). 
                                           
36 See: George Loizou and Alex Hogg, "MEGen: A Physiologically Based Pharmacokinetic 
Model Generator", Front. Pharmacol. 2011; 2: 56 (online: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212724/) 
37 http://cefic-lri.org/  
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3.1 EDITOX: Assessent of the Risk for Chemicals to Induce 
Psychiatric Adverse Side Effects (Depression and/or Suicide)  
The test method consists of the quantitative analysis of RNA editing modifications of the 
serotonin receptor 2C (5-HT2cR) induced by pharmaceutical compounds using SH-SY5Y 
human neuroblastoma cell line. The test is based on the observation that anomalies of 
serotonin biology in brain appear to be a characteristic feature underlying depression 
and/or suicidal behaviour. This assumption has been suggested based on analyses of 
postmortem brain tissue of suicide victims where distinct epigenetic alterations of the 
RNA editing activity on 5-HT2cR pre-mRNA has been observed. The test method can 
quantitatively analyse variations of the relative proportion of the 32 mRNA editing 
isoforms of 5-HT2cR using a next generation sequencing approach. The submitter claims 
that predictive performances of the submitted test outcompete current test methods 
using behavioural animal models. The test submission is currently under evaluation by 
EURL ECVAM. 
3.2 Bioaccessibility Testing (Bioelution)  
A pre-submission of an in vitro method (bioelution) was received in 2016. The method is 
not a toxicity test but will provide the fraction of a substance that dissolves under 
surrogate physiological conditions and is potentially available for absorption into 
systemic circulation. This is termed bioaccessibility, which can be considered as a 
conservative estimate of bioavailability. The method estimates relative bioaccessibility of 
metal ions from various metal-containing materials in simulated gastric fluid, by 
comparing the target and the reference material. The in vitro bioelution method is then 
proposed by the test submitter to generate bioaccessible metal ion data for the oral 
route of exposure, which is relevant to systemic effects of metal-containing materials. 
The test submission is currently under evaluation by EURL ECVAM. 
3.3 Ashland Reconstructed Human Epidermis Skin Irritation Test  
EURL ECVAM received a pre-submission on the Ashland skin irritation test in May 2015 
proposing the conduct of a Performance Standards-based validation study. A reply was 
sent to the test method submitters identifying a number of shortcomings that should be 
addressed before embarking on the validation study and therefore, the submission was 
not progressed. Seeing that the submitters' intention is to include their test method in 
OECD TG 439, EURL ECVAM also suggested that they contact a National Coordinator 
(NC) for the OECD Test Guidelines Programme to seek support for a submission to the 
OECD and discuss the steps involved in such a submission. Following this expedited 
route for regulatory acceptance, the developers of the Ashland skin irritation test would 
be able to submit their validation report directly to the OECD for review by the 
appropriate expert group after successful completion of their validation study, without 
the need to go through further evaluation by EURL ECVAM and peer review by the EURL 
ECVAM Scientific Advisory Committee (ESAC). EURL ECVAM may still contribute, 
together with other OECD member countries/organisations, to the review of the 
validation study report via the usual OECD process. 
3.4 SkinEthic™ Human Cornea Epithelium (HCE) Eye Irritation 
Test 
In December 2008, two reconstructed human eye tissue models for in vitro assay of eye 
irritation potential, EpiOcular™ EIT and SkinEthic™ HCE, were sponsored for validation 
as alternatives to the traditional in vivo standard practice (Draize test) with rabbits 
(OECD 2012). The eye irritation validation study (EIVS) was conceived as a ring trial of 
comparative performance among six participant laboratories, testing selected chemicals 
to evaluate reliability (reproducibility of results obtained in vitro) and relevance 
(predictive capacity of effects documented in vivo). Neither test method was able to 
comply fully with the acceptance criteria set by the validation management group 
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(VMG). Therefore, further optimisation was recommended. With minor refinement to the 
EpiOcular™ EIT protocol, the method was successfully validated in 2013. The SkinEthic™ 
HCE protocol was subject to more comprehensive revision, followed by another 
validation ring trial (three laboratories) completed in 2015. In November 2015 the 
revised SkinEthic™ HCE test method was submitted for assessment by EURL ECVAM and 
formal validation by ESAC peer review. 
The SkinEthic™ HCE method is suited to so-called Top-Down/Bottom-Up assessment 
(Scott et al., 2010) particularly relevant for chemicals used in human exposure products, 
such as cosmetics ingredients which are banned from animal testing. In this context the 
SkinEthic™ HCE method is applicable as a first step in Bottom-Up discrimination of 'non-
irritants (GHS no category; UN Nations GHS, 2013) or as a confirmatory last step in Top 
Down identification of 'irritants' (GHS categories 1 and 2). However, the method is not 
intended to differentiate category 1 from 2. 
The follow-up validation (ring trial, three laboratories) evaluated within/between 
laboratory reproducibility (WLR/BLR) and predictive capacity (PC) including 120 
chemicals (60 liquids, 60 solids) with an additional 80 chemicals (45 liquids, 35 solids) 
tested by the lead laboratory. Overall, WLR/BLR was greater than 90%. PC compares in 
vitro viability with documented in vivo classification (true versus false predictions) 
respective of irritant classification (C) and non-irritant classification (NC). Overall 
sensitivity (correct prediction of C) was 98% (liquids) and 92% (solids). Overall 
specificity (correct prediction for NC) was 69% (liquids) and 77% (solids). Overall 
accuracy (correct prediction, C or NC) was 85% (liquids) and 84% (solids).  
The SkinEthic™ HCE method and validation study underwent scientific peer review by 
ESAC in June 2016 with a positive outcome (see 4.7) 
3.5 Sterlab Reconstructed Human Epidermis Skin Irritation Test  
EURL ECVAM received a full submission on the Sterlab RHE for skin irritation testing in 
June 2015. A reply was sent to the test method submitters raising several issues for 
their consideration and a revised submission was received in May 2016. In reply to this 
latest submission EURL ECVAM clarified its recent position not to proceed with a formal 
assessment and peer-review of the Sterlab RHE nor of any other methods similar to the 
already validated and accepted RhE-based skin irritation test methods described in OECD 
TG 439 (so-called "me-too" methods). Seeing that the submitters' aim is to include their 
test method in OECD TG 439, EURL ECVAM believes that a direct submission to the 
OECD would expedite the acceptance of the method and therefore recommended that 
the developers of the Sterlab RHE engage directly with a National Coordinator (NC) of 
the OECD Test Guideline Programme and seek the NC's immediate support to include the 
Sterlab RHE in the OECD Work Programme. Following this expedited route for regulatory 
acceptance, the developers of the Sterlab RHE would be able to submit their validation 
report directly to the OECD for peer-review by the appropriate expert group without the 
need to go through further evaluation by EURL ECVAM and peer review by the EURL 
ECVAM Scientific Advisory Committee (ESAC). EURL ECVAM may still contribute, 
together with other OECD member countries/organisations, to the review of the 
validation study report via the usual OECD process. 
3.6 SENS-IS Skin Sensitisation Test  
The SENS-IS assay provides an in vitro method for identifying potential skin sensitising 
substances. The test method is based on a reconstructed human skin model as the test 
system and on the analyses of the expression of three groups of genes by a 
toxicogenomic approach [Quantitative Reverse Transcription-Polymerase Chain Reaction 
(qRT-PCR)] measuring fold increase in the expression levels of genes over a calibrator 
control (Cottrez et al., 2015). Besides providing information on the potential or not of a 
chemical to act as sensitiser, the method also allows to classify substances predicted to 
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be sensitisers in one of four potency classes (weak, moderate, strong and extreme) on 
the basis of the lowest concentration tested. 
The Sens-is test method underwent an external validation study coordinated by 
ImmunoSearch (Grasse, France) to evaluate the within- and between-laboratory 
reproducibility and the preliminary predictive capacity of the method using results 
generated with 19 chemicals tested in three different laboratories (Cottrez et al., 2016). 
Additional evidence on the predictive capacity of the method for positive/negative 
classification and for potency subcategorisation is available for a total of 150 substances 
tested at the ImmonoSearch laboratory. The information generated during the validation 
study has been submitted to EURL ECVAM and is currently under evaluation for 
adequateness to enter the peer-review process.  
The development of a Test Guideline for the SENS-IS is already included in the OECD 
work program. The fact that the test method includes proprietary elements that may 
lead to a situation of market monopoly was originally seen as a reason of concern. The 
issue of intellectual property (IP) in Test Guidelines was discussed in occasion of the 
27th meeting of the OECD Working Group of the National Coordinators for the Test 
Guidelines Programme (WNT) in 2015. Generally, the WNT agreed that "it is important 
that the Test Guidelines Programme continues to develop test methods that make use of 
the best available technology, provided there is transparency on important mechanisms 
that enable users to understand how test results are generated and interpreted, i.e. 
avoiding a ‘black box’ test system. It was recognised that the possible monopoly 
situation by one test method developer may be unavoidable from time to time, until 
similar methods are developed; this situation should not be seen as a problem provided 
there is no abuse and there is transparency in the functioning of the test method".
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4 Validation of Alternative Methods 
4.1 Androgen Receptor Transactivation Assay AR-CALUX  
In view of developing an OECD Performance Based Test Guideline (PBTG) for Androgen 
Receptor Transactivation Assays (ARTAs), EURL ECVAM is carrying out a validation study 
of the in vitro method AR-CALUX.  This method is a reporter-based assay where 
osteosarcoma cells, stably transfected with a human androgen receptor, will express 
luminescence when presented with chemicals that have (anti)androgenic potential.  The 
method was submitted by the Dutch company BioDetection Systems (BDS). From EURL 
ECVAM's network of specialised laboratories, the European Union Network for the 
Validation of Alternative Methods (EU-NETVAL), three facilities are participating in this 
validation study. A Validation Management Group to provide oversight on the study has 
been established. So far, EURL ECVAM has carried out an experimental assessment of 
the method; conducted a GLP study in order to refine the assay and establish transfer 
criteria; provided a training for the three partner facilities at the JRC laboratories in 
Ispra; coordinated the first phase of the validation study, the transfer phase, where the 
three participating labs have applied the method in their own laboratories. This phase 
was recently finalised. Besides the AR-CALUX method, the PBTG on ARTAs and related 
Performance Standards will also be based on other ARTAs either already validated or in 
the process of a validation: the AR STTA using the AR-EcoScreen cell line (led by Japan, 
recently accepted and issued as TG 458, see Annex 1) and the ARTA using the 
22Rv1/MMTV cell line (led by Korea, see Annex 2). EURL ECVAM participates in the latter 
study as a member of the VMG, providing support with the chemicals selection, study 
design and data interpretation.  
4.2 Micronucleus Test and Comet assay in Reconstructed Skin 
Models for Genotoxicity Testing 
The validation of methods for genotoxicity testing in reconstructed human 3D skin 
models, coordinated by Cosmetics Europe, is still ongoing (Aardema et al., 2010;Reus et 
al., 2013). The experimental work for the micronucleus test in 3D epidermis model has 
been finalised and data are being evaluated using the assessment criteria considered in 
the updated OECD Test Guidelines for genotoxicity. For the comet assay in full-thickness 
skin models the between-laboratory reproducibility and predictive capacity is still being 
assessed. Both the micronucleus and the comet assay in reconstructed skin models will 
not be considered as stand-alone assays, but they will be used within an animal-free 
testing strategy for genotoxicity to follow-up the in vitro testing battery results. 
4.3 Hen's Egg test for Micronucleus Induction (HET-MN) for 
Genotoxicity Testing  
The hen's egg test for micronucleus induction (HET-MN; Wolf et al., 2008) has also been 
proposed as a follow-up test method for in vitro positives in a testing strategy for 
genotoxicity. The HET-MN combines the use of the commonly accepted genetic endpoint 
“formation of micronuclei” with the well-characterised and complex model of the 
incubated hen's egg, which enables metabolic activation, elimination and excretion of 
xenobiotics, including those that are mutagens or pro-mutagens. The predictive capacity 
of the assay is currently being evaluated by a German consortium (Greywe et al., 2012). 
4.4 Ongoing Validation Studies for Vaccine Quality Control – 
EDQM Biological Standardisation Programme  
Most of the validation studies on alternative methods for vaccine quality control are 
carried out within the framework of the Biological Standardisation Programme (BSP) of 
the European Directorate for the Quality of Medicines & HealthCare (EDQM; Council of 
Europe) and co-sponsored by the European Commission.  
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Several validation studies are currently ongoing which assess alternative methods for the 
safety and potency testing of human and veterinary vaccines (e.g. a serological assay 
for the potency testing of whole-cell pertussis vaccines; a multi-dose serological assay 
for rabies vaccine for veterinary use; in vitro methods for the testing of Clostridium 
septicum vaccines, the BINACLE assay for in vitro detection of toxicity in tetanus 
vaccines) or are planned for 2016 and beyond (e.g. ELISAs for tetanus/diphtheria 
vaccines, ELISA for potency testing of human rabies vaccines).  
More information on the BSP, its background and work programme is available at 
https://www.edqm.eu/en/BSP-Work-Programme-609.html. 
As reported in last year's EURL ECVAM status report, the results of a validation study on 
alternative methods to the murine histamine sensitisation test (HIST) for safety testing 
of acellular pertussis vaccines indicated that the "indirect CHO-cell based assay" is a 
suitable alternative for replacement of HIST. The final outcome of the study has recently 
been published (Isbrucker et al., 2016) and inclusion of the method into the relevant 
monographs is ongoing.  
In collaboration with EPAA, EDQM discussed the results of Phase 2 of the project on in 
vitro methods for the testing of Clostridium septicum vaccines at a workshop in 
September 2015 (Sinitskaya et al., 2016). Phase 3 has been launched and more details 
are given under 5.9.4.  
4.5 Update on the European Union Network for the Validation of 
Alternative Methods (EU NETVAL)  
EURL ECVAM established a network of 37 highly qualified laboratories (EU-NETVAL)38 to 
(1) respond to the provision of Directive 2010/63/EU asking to set up a network of 
suitable specialised and qualified laboratories to carry out validation studies, (2) 
generate in vitro method information that is reliable, relevant and based on current best 
quality and scientific practices, (3) increase the European Commission's validation 
capacity of in vitro methods and (4) provide a laboratory network knowledgeable on the 
routine implementation of good in vitro method practices for regulatory use in human 
safety assessment (Coecke et al., 2014). The network has recently expanded to include 
thirteen new test facilities (bringing the total to 37). Fifteen countries are now 
represented in the network (from EU Member States and European Free Trade 
Association countries) following the call for membership of EU-NETVAL which closed in 
September 2015. The current network holds a range of expertise and competences and 
includes laboratories experienced in advanced in vitro procedures, test systems and 
measurement techniques. These are considered important to address specific aims and 
objectives identified in EURL ECVAM's strategies to achieve Three Rs impact in different 
areas of regulatory safety testing.  
EU-NETVAL members support validation studies through the execution of one or more 
specific tasks39. The first pilot validation project of selected EU-NETVAL test facilities is 
the generation of experimental data using the in vitro AR-CALUX method to support the 
development of an OECD Performance-based Test Guideline and associated performance 
standards for Androgen Receptor Transactivation Assays (ARTA) for the detection of 
compounds with (anti)androgenic potential (see 4.1). Also defined in the Terms of 
Reference39, the network contributes to the development of guidance documents and 
training materials supporting good in vitro method development and practices. They 
have provided input to the technical guidance document, Good In Vitro Method Practice 
(see 5.6.11) and are currently in the process of reviewing this document in view of 
submission to the OECD.  
                                           
38 https://eurl-ecvam.jrc.ec.europa.eu/eu-netval-test-facilities  
39 https://eurl-ecvam.jrc.ec.europa.eu/eu-netval/EU-NETVAL-tor-november-2013.pdf  
 19 
 
In addition to the wide range of techniques and capabilities, the network offers an 
opportunity to share knowledge and to collaborate for the promotion of the development 
and use of alternative approaches. A survey was carried out from November 2015 until 
15th January 2016 to inform a report on the training needs and competences within EU-
NETVAL and to identify opportunities to share knowledge and best practice. Twenty-nine 
test facilities responded to the survey out of a total of the thirty-six which were 
members at the time of the survey. A summary of the responses will be presented in a 
report along with the opportunities for collaborative training that EURL ECVAM has 
identified.  
4.6 EURL ECVAM Guidance on the Validation of Alternative 
Methods to Animal Testing 
Nowadays, an increasing number of validation studies are conducted by external parties 
(e.g. industry, academia, consortia). Often these studies are conducted by experts in 
specific technologies, but not in validation. Therefore, EURL ECVAM is preparing a 
Guidance Document that will support validation studies in terms of study design, 
management, reporting, and transparency. Hence, it will facilitate evaluation, peer-
review, regulatory acceptance and international recognition of methods which have 
undergone a prospective validation study. After a brief introduction to validation (What is 
it about? Why is it necessary?), the document will guide the test submitter through the 
four stages of a prospective validation study: planning, conducting, analysing and 
reporting. Criteria for a preliminary assessment will also be covered, to evaluate at an 
early stage whether the method is ready for validation. While there are excellent 
documents on validation, regulatory acceptance and minimum reporting requirements of 
novel methods (i.e. OECD guidance document No. 34, 2005) this guidance attempts to 
provide assistance on how to practically carry out validation. 
4.7 EURL ECVAM Scientific Advisory Committee Peer Reviews  
From April to June 2016, the EURL ECVAM Scientific Advisory Committee (ESAC) 
reviewed five test methods and their respective validation studies that had been 
submitted to EURL ECVAM for evaluation and peer-review. These were (i) the 
Performance Standards-based validation study of the epiCS® Skin Irritation Test (SIT) 
coordinated by CellSystems GmbH, (ii) the validation of the Ocular Irritection® test 
method for prediction of serious eye damage/eye irritation potential of chemicals 
coordinated by Secam Services & Consultation on Alternative Methods Sagl., (iii) the 
validation study of the SkinEthic™ Human Corneal Epithelium (HCE) Eye Irritation Test 
(EIT) coordinated by L'Oréal, (iv) the validation study of the U-SENS™ test method for 
skin sensitisation testing coordinated by L'Oréal, and (v) the Performance Standards-
based validation study of the LuSens test method for skin sensitisation testing 
coordinated by BASF. Two ESAC Rapporteurs coordinated the peer-review of the epiCS® 
SIT, whereas the peer-review of the other four methods was coordinated by two newly 
appointed ESAC Working Groups composed of ESAC members and experts on eye 
irritation or skin sensitisation nominated by EURL ECVAM and ICATM partners. The ESAC 
Working Group on eye irritation met at EURL ECVAM on 11-13 May 2016 to conduct the 
review of the SkinEthic™ HCE EIT and of the Ocular Irritection® assay. The ESAC 
Working Group on skin sensitisation met at EURL ECVAM on 17-19 May 2016 to conduct 
the review of the U-SENS™ and of the LuSens test methods. Working Group/Rapporteur 
reports and ESAC Opinions on each individual method were discussed and endorsed by 
ESAC at its 42nd meeting (ESAC42) on 9-10 June 2016. A sixth ESAC Opinion on the use 
of Performance Standards to evaluate test methods similar to a Validated Reference 
Method was also issued at ESAC42. The six ESAC Opinions will be published by EURL 
ECVAM during autumn 2016. 
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4.8 EURL ECVAM Recommendations 
There are currently two EURL ECVAM Recommendations in preparation and one planned. 
One relates to the use of non-animal methods and approaches based on data integration 
for skin sensitisation assessment including the recently peer reviewed LUSENS and U-
SENS test methods (see 4.7). The other EURL ECVAM Recommendation is on the human 
cytochrome P450 (CYP) n-fold induction in vitro test methods which underwent 
independent scientific peer review last year (see 4.6.3 of EURL ECVAM status report 
2015, Zuang et al., 2015). A third recommendation related to reconstructed human 
cornea-like epithelium test methods for serious eye damage/eye irritation including the 
EpiOcular™ EIT and the recently peer reviewed SkinEthic™ HCE EIT (see 4.7) methods is 
also planned. 
The draft EURL ECVAM recommendation on skin sensitisation may be supplemented by 
relevant points raised at the upcoming International Cooperation on Alternative Methods 
(ICATM) meeting on the international regulatory applicability and acceptance of 
alternative approaches to skin sensitisation assessment of chemicals (see 7). Once 
finalised, all draft recommendations will follow the normal consultation process of EURL 
ECVAM's network of regulators (PARERE; see 5.1.1), its Stakeholder Forum (ESTAF; see 
5.1.2) and the International Cooperation on Alternative Methods (ICATM; see 7). 
 
5 Promoting the Regulatory Acceptance and use of 
Alternative Methods and Approaches 
5.1 PARERE (Preliminary Assessment of Regulatory Relevance) 
and ESTAF (ECVAM Stakeholder Forum) Annual Meetings 
EURL ECVAM organises annual meetings with the Preliminary Assessment for Regulatory 
Relevance network (PARERE) and the EURL ECVAM Stakeholder Forum (ESTAF). In 
2015, the meetings took place on 20th and 21st October. 
5.1.1 PARERE Meeting 2015 
At this meeting, PARERE members gave an overview on the status of the establishment 
of the PARERE network in their respective countries, including the involvement of 
national bodies/agencies/experts, as well as a brief description of its functioning and 
difficulties encountered.  
The PARERE consultation process on a test method for teratogenicity testing (devTOXqP) 
was launched in 2014. EURL ECVAM presented the results of this consultation on the 
regulatory relevance of the method. The summary of the PARERE consultation has been 
finalised and transferred to the test submitter.  
In relation to the priority needs identified by EURL ECVAM, discussions covered: 
 Bioelution Test Method 
 Reproductive and developmental toxicity 
Participants provided their views on these points and were asked to continue these 
discussions within their networks to generate ideas for these areas.  
5.1.2 PARERE ESTAF Joint Meeting 2015 
The joint meeting of PARERE and ESTAF on 20th October focused on Integrated 
Approaches to Testing and Assessment (IATA), including a workshop.  The aim of the 
workshop was to discuss key issues relating to the development, evaluation, acceptance 
and use of IATA with a view to identifying the pros and cons of different options for 
promoting the acceptance of IATA. 
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EURL ECVAM presented four case studies (serious eye damage/eye irritation, skin 
sensitisation, endocrine disruption and acute systemic toxicity) to demonstrate the 
concept of an IATA in relation to each area and to prepare the groups for the workshop. 
The meeting and workshop summary records have been published by EURL ECVAM40.  
5.2 Promoting the Regulatory Acceptance in the context of REACH  
5.2.1 Update of REACH Annexes to Reflect Scientific Progress:  
5.2.1.1 Skin Corrosion/Irritation and Serious Eye Damage/Eye Irritation  
In June 2016, new amendments to the REACH Annexes VII and VIII regarding skin 
corrosion/irritation (point 8.1 of Annexes VII and VIII) and serious eye damage/eye 
irritation (point 8.2 of Annexes VII and VIII) entered into force (EC, 2016a), following 
the favourable vote in December 2015 of the REACH Committee on the proposal from 
the European Commission to change the standard information requirement under Annex 
VIII to in vitro studies. The driver of these amendments was the significant scientific 
progress made in recent years in the development, validation and regulatory acceptance 
of alternative test methods for the assessment of skin corrosion/irritation and serious 
eye damage/eye irritation. 
The revised legal text points out that for skin corrosion/skin irritation, adequate 
information for the classification and risk assessment of a substance may be obtained in 
most cases solely on the basis of in vitro studies. A conclusion may be drawn on the 
basis of one in vitro test method, if the result allows an immediate decision on 
classification or non-classification, or from a combination of two in vitro test methods, 
one for skin irritation and one for skin corrosion. In vivo studies may still be required in 
some exceptional cases for substances manufactured or imported in quantities of 10 
tonnes or more, e.g. when the substance tested falls outside the applicability domain of 
the in vitro test methods or when no conclusive results can be obtained from a 
comprehensive set of in vitro data. For serious eye damage/eye irritation, a set of in 
vitro test methods exists which would be sufficient in many cases to obtain information 
adequate for classification and risk assessment of substances. A conclusion about the 
potential of a substance to cause such eye effects may be drawn on the basis of one test 
method, if the result allows an immediate decision on classification or non-classification, 
or from a combination of two or more test methods. In vivo studies may still be required 
in some cases for substances manufactured or imported in quantities of 10 tonnes or 
more, e.g. when the substance tested falls outside the applicability domain of the test 
methods or when no conclusive results can be obtained from a comprehensive set of in 
vitro data. 
In addition, the standard information requirements and adaptation rules in points 8.1, 
and 8.2 of Annex VII, and the adaptation rules in points 8.1 and 8.2 of Annex VIII were 
also revised in order to remove redundancies with rules set by Annex VI and Annex XI 
and in the introductory parts of Annexes VII and VIII as regards the review of available 
data, the waiving of studies for a toxicological endpoint if the available information 
indicates that the substance meets the criteria for classification for that toxicological 
endpoint, or to clarify the intended meaning as regards the waiving of studies for 
substances that are flammable under certain conditions. 
5.2.1.2 Skin Sensitisation  
The regulatory adoption by the OECD of the first three non-animal methods for skin 
sensitisation testing, the Direct Peptide Reactivity assay (DPRA; OECD, 2015a), the 
KeratinoSens™ (OECD, 2015b) and the human Cell Line Activation Test (h-CLAT; OECD, 
2016c) addressing key mechanisms of the skin sensitisation pathway, was the driver of 
                                           
40 https://eurl-ecvam.jrc.ec.europa.eu/about-ecvam/scientific-advice-stakeholders-net 
works/parere  
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the revision of the REACH information requirements for the endpoint, laid down in Annex 
VII (≥1t/year) of the REACH regulation. 
In April 2016, the REACH Committee voted in favour of a proposal from the European 
Commission to make the adopted in chemico/in vitro methods the default requirement 
(EC, 2016a).  The revised provisions are unequivocal in asking that each of the following 
skin sensitisation key events should be addressed: 1) molecular interaction with skin 
proteins, 2) inflammatory responses in keratinocytes and 3) activation of dendritic cells.  
An in vivo study should only be conducted if the non-animal test methods are not 
applicable, or if the test results are not adequate for classification and risk assessment. 
In such cases, the murine local lymph node assay (LLNA) still needs to be used. The 
revised legal text also foresees that a substance predicted to have skin sensitisation 
hazard should be further evaluated to assess whether it can be presumed to have the 
potential to produce significant sensitisation in humans (Cat. 1A). 
The revised legal text, accessible at: http://eur-lex.europa.eu/legal-
content/FR/TXT/?qid=1475073772590&uri=CELEX:32016R1688, will entry into force in 
October 2016 and, therefore, will have important implications for the REACH 2018 
registration deadline. 
 
5.2.1.3 Acute Systemic Toxicity  
In June 2016, the REACH amendment concerning acute dermal toxicity (point 8.5 of 
Annex VIII) has been published (EC, 2016b), following the favourable vote in December 
2015 of the REACH Committee on the proposal from the European Commission to waive 
an acute dermal toxicity study for those substances which are non-toxic via the oral 
route. The driver of this revision was the existing evidence from several scientific 
analyses of available data indicating that substances demonstrated to be of low acute 
toxicity by the oral route are also of low toxicity by the dermal route and, therefore, that 
dermal testing for acute systemic toxicity of such substances adds nothing to the hazard 
characterisation (e.g. Creton et al., 2010; Seidle et al., 2011, Moore et al., 2013). 
The revised legal text makes clear that testing by the dermal route can be waived if the 
substance is not classified via the oral route (LD50 > 2000 mg/kg bw (body weight)/d) 
and no systemic effects have been observed in in vivo studies with dermal exposure or, 
in the absence of such in vivo studies, no systemic effects after dermal exposure are 
predicted on the basis of non-testing approaches. 
The revised legal text is expected to entry into force in autumn 2016 and, therefore, will 
have important implications for the REACH 2018 registration deadline. 
5.3 Update of REACH Guidance on Information Requirements and 
Chemicals Safety Assessment 
5.3.1 Skin Sensitisation  
Advances in the area and more importantly the revision of the legal text in Annex VII to 
the REACH Regulation (see 5.2.1.2) have also prompted an update of the European 
Chemicals Agency's (ECHA) guidance to industry on Information Requirements and 
Chemical Safety Assessment (Chapter R 7.a, section R.7.3 Skin sensitisation; ECHA, 
2016a). The revised ECHA draft guidance provides a description of the scope and 
limitations of the adopted alternative methods. Since the new in chemico/in vitro test 
methods should not be used as stand-alone methods due to test method specific 
limitations, a combination of these methods should be used. Additional information 
obtained from other approaches such as (Q)SARs or read-across may assist in making 
an adequate conclusion that is suitable for classification and risk assessment. 
With a view to assist registrants fulfilling the information requirements under REACH the 
revised guidance proposes a testing and assessment strategy which comprises three 
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parts. Part 1 is about retrieving existing information, Part 2 consists of the Weight-of-
Evidence (WoE) assessment and Part 3 is about the generation of new information by 
testing if needed. The strategy aims to help registrants to use information from in 
chemico/in vitro methods for skin sensitisation according to Annex VII, section 8.3.1, or 
in a WoE approach according to sections 1.2-1.5 of Annex XI on "General Rules for 
Adaptation of the Standard Testing Regime set out in Annexes VII to X". 
Although the guidance recommends the testing and assessment strategy to be followed, 
it acknowledges that other approaches may be more appropriate depending on the 
specific case. 
5.3.2 Acute Systemic Toxicity  
ECHA is currently undergoing the process of updating section R.7.4 (acute toxicity) of 
the Guidance on Information Requirements and Chemical Safety Assessment Chapter 
R.7a: Endpoint specific guidance41. 
EURL ECVAM has provided ECHA with strategy documents and data analyses to support 
the updating of the ECHA guidance document. In this regard, EURL ECVAM conducted in 
2015 an online survey aimed at experts in the field of acute systemic toxicity testing to 
explore potential waiving opportunities for acute oral toxicity tests. The findings from 
this survey were supported by a retrospective data analysis of REACH-registered 
chemicals that explored whether it is possible to predict the outcome of an acute oral 
toxicity study (i.e. lethality) from the outcome of a 28-day repeated dose toxicity study. 
The JRC analysis and the outcome of the survey have been published (Graepel et al., 
2016). 
Moreover, EURL ECVAM was invited by ECHA and nominated by JRC to participate in a 
Partner Expert Group (PEG) responsible for reviewing and commenting on ECHA's 
proposed updates to this section of the Guidance. The written consultation of the PEG 
was initiated in October 2015. ECHA received a total of 346 comments of which 59 were 
provided by EURL ECVAM. Forty nine of the 346 comments were prioritised by ECHA for 
discussion during the meeting. The great majority of EURL ECVAM's comments were 
accepted by the PEG members and ECHA. These were aimed mostly to making sure that 
1) a proper reference is made in the updated guidance to the available scientific analysis 
of data that showed the predictive performance of several QSAR tools and the in vitro 
3T3 NRU test method; 2) the Guidance text is aligned with the revised legal text of the 
REACH Annex VIII section 8.5.3. (i.e. waiving a dermal toxicity study if no acute oral 
toxicity is observed up to the limit dose of 2000 mg/kg b.w.) once it is published; 3) the 
update of the Guidance reflects the current status of development of the different new or 
revised EU Test Methods and/or OECD Test Guidelines for acute inhalation and dermal 
toxicity; 4) the dose range finding studies described under the WoE adaptation approach 
are revised to clarify whether all of them are needed and/or recommended and the real 
impact on animal testing; 5) the acute inhalation OECD TGs which use fewer animals are 
included in the figures of the acute testing strategy. 
The PEG meeting took place at ECHA in December 2015 to discuss the comments 
received from the PEG members and to further consolidate the updated guidance. In 
May 2016 the consolidated version, which already considered the revised REACH Annex 
VIII voted by the REACH committee in December 2015, was sent to PEG members for 
final cross-check with the possibility to make additional comments. The new draft 
version was subsequently submitted to ECHA's Member State Committee and the 
Committee for Risk Assessment and no comments were received. 
A final consultation with the Competent Authorities for REACH and CLP (CARACAL) was 
initiated in July 2016 (21st CARACAL meeting) and no comments were received by the 
                                           
41 https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
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deadline of 16 September 2016. The target date for publication of this guidance update 
is foreseen in October 2016 on the ECHA website. 
5.4 VICH Guidelines on Vaccines: Harmonisation of Criteria for 
Waiving of Target Animal/Laboratory Animal Batch Safety 
Testing of Vaccines for Veterinary Use 
The requirements on batch safety testing differ between the various geographic regions. 
For example, general safety tests for batch release of human and veterinary vaccines are 
no longer required in Europe and have been deleted from European Pharmacopoeia 
monographs several years ago (abnormal toxicity test; Schwanig et al., 1997) or 
recently (target animal batch safety test; EDQM, 2012). Since these tests may still be 
required outside of Europe, European manufacturers may need to carry out these tests 
when exporting to third countries. 
Since 2008, EURL ECVAM is working on behalf of EMA with VICH experts on the 
development of VICH guidelines on harmonisation of criteria to waive the target animal 
batch safety testing for inactivated and live vaccines for veterinary use. VICH GL50 for 
inactivated veterinary vaccines was adopted in 2013 and is in force since 1st March 2014 
(VICH, 2013). The comparable VICH GL55 for live veterinary vaccines and the revised 
VICH GL50 underwent public consultation in 2016 and are currently being finalised for 
adoption by the VICH Steering Committee. 
A third guideline is under development aiming at the harmonisation of criteria to waive 
the general batch safety test in laboratory animals (e.g. abnormal toxicity test).  
5.5 Activities in the OECD Task Force on Hazard Assessment 
5.5.1 Update on Guidance Documents on Defined Approaches for Skin 
Sensitisation 
EURL ECVAM led on behalf of the European Commission an OECD project aimed at the 
development of guidance documents on the reporting of Defined Approaches (DA). A 
defined approach to testing and assessment consists of a fixed data interpretation 
procedure (DIP) applied to data generated with a defined set of information sources to 
derive a result that can either be used on its own, or together with other information 
sources within an IATA, to satisfy a specific regulatory need. The concept of DIP, taken 
from OECD guidance document 34 (OECD, 2005), is defined as any algorithm for 
interpreting data from one or more information sources. The output of a DIP is typically 
a prediction (e.g. prediction of skin sensitisation potential from peptide binding data 
and/or chemical structure). Thus, a DA in contrast to the assessment process within 
IATA does not imply expert judgment in deriving the final prediction/assessment.  
DA should be documented to the extent possible to facilitate their evaluation, or the 
evaluation of IATA in which they are used as one of the components, in regulatory 
decision-making. 
In June 2016 the OECD Task Force on Hazard Assessment (TFHA) endorsed two GD on 
the reporting of DA. The first GD (OECD, 2016a) provides a set of principles for the 
reporting of DA. To facilitate its regulatory use a DA should be associated with the 
following set of information: 1) a defined endpoint, 2) a defined purpose, 3) a 
description of the underlying rationale, 4) a description of the individual information 
sources used within, 5) a description of how data from the individual information sources 
are processed and 6) a consideration of the known uncertainties associated with the 
application of the DA. The GD also provides reporting templates organised on the basis 
of these principles to enable the structured documentation of DA and the individual 
information sources. Beside other elements, emphasis is put in the templates on the 
proper reporting of the limitations in the application of the DA, of its predictive 
performance and of the sources of uncertainties that may impact on the final prediction.  
These templates should be used alongside the reporting formats for other IATA 
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components, such as QSARs (OECD, 2007a), grouping and read-across strategies 
(OECD, 2014a) and non-guideline test methods (OECD, 2014b). 
The second GD (OECD, 2016b) exemplifies how the reporting templates have been used 
to document a number of DA developed in the area of skin sensitisation. These 
approaches are based on the use of information sources addressing key 
mechanisms/events of the skin sensitisation AOP and make use of a variety of specific 
methodologies, i.e. DIP, for converting the input data/parameters into a final prediction. 
The case studies provide a good overview of the different set of information sources and 
DIP that can be used within DA. The DIP can range from very simple rule-based 
sequential decision steps to mathematical and statistical approaches. It is not the intent 
of this document to seek for endorsement of any specific defined approach provided in 
the case studies, but rather provide a perspective of how individual information sources 
and defined approaches developed for skin sensitisation assessment should be reported. 
Although there is not yet experience with the use of the developed templates for 
reporting DA in other areas of toxicology, it is envisaged that their application is not 
limited to the reporting of DA for skin sensitisation. 
5.5.2 IATA Case Studies Project including the JRC-CosEU ab initio Case 
Study  
The IATA Case Studies Project under the OECD TFHA was set up to support efforts of the 
OECD member countries to increase the use of alternative methods within Integrated 
Approaches for Testing and Assessment (IATA), in particular by developing respective 
guidance and tools. The project is investigating the practical applicability of IATA by 
discussing case studies, based on a draft template 42 , and by summarising the 
considerations to create a common understanding of using the approaches. The first 
cycle in 2015 comprised four case studies focused on grouping and read-across for 
different hazard endpoints 43 (OECD, 2016d-g), including discussions on the need for 
specific guidance (OECD 2016h). In the 2016 cycle, five case studies 44  have been 
reviewed, including not only grouping approaches, but also two studies based on initial 
SEURAT-1 read-across work submitted by ICAPO, as well as the JRC/BIAC submission of 
the chemical safety assessment workflow based on exposure considerations and focusing 
on non-animal methods, developed from the SEURAT-1 cross-cluster ab initio case study 
(Richarz et al., 2016). The workflow attempts to structure knowledge and data in a 
logical sequence for an integrated chemical safety assessment. It includes considerations 
of Threshold of Toxicological Concern (TTC), read-across approaches and application of 
physiologically-based kinetic (PBK) modelling to identify target organs and internal 
concentrations. In silico profilers and in vitro data generation contribute to building a 
weight of evidence, based on an AOP-anchored mode-of-action hypothesis, supported by 
in vitro to in vivo extrapolation (IVIVE) modelling and refinement. The case study 
highlights the challenge in integrating multiple data streams for safety assessment 
decisions. 
                                           
42 Developed based on OECD (2014c) and OECD (2014d)  
43 In vitro mutagenicity of 3,3’ dimethoxybenzidine (DMOB) based direct dyes (Canada, 
United States), repeated-dose toxicity of substituted diphenylamines (SDPA) (Canada), 
hepatotoxicity of allyl esters category (Japan), bioaccumulation potential of degradation 
products of 4,4'-bis (chloromethyl)-1,1'-biphenyl (Japan) 
44 Structure related repeated-dose toxicity profiles assessment by using toxico-genomics 
data (Japan), pesticide cumulative risk assessment (United States), read-across of 90-
day rat oral repeated-dose toxicity for selected n-alkanols and 2-alkyl-1-alkanols 
(ICAPO), chemical safety assessment workflow based on exposure considerations and 
non-animal methods (JRC/BIAC) 
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5.5.3 Combined Exposure to Chemical Mixtures  
Humans and the environment are continuously exposed to a multitude of substances via 
different routes of exposure. The toxicological risk of chemical mixtures, relates both to 
intentional mixtures (e.g. known compositions, such as personal care products, food 
additives and pesticides) and unintentional ones (e.g. the combination of dozens to 
hundreds of substances in surface water, drinking water or air). For the latter, the 
assessment is much more challenging because (a) the compositions are various and 
complex, (b) many of the substances are unidentified and toxicity data are lacking. The 
current risk assessment approach of chemicals, for regulatory purposes, does not 
generally take into account this complex situation of exposure to multiple substances 
and mainly relies on the assessment of individual substances. Moreover, although the 
current EU regulations identify different types of mixtures, there is no harmonised 
methodological approach to their assessment.  
This gap in the EU regulatory assessment framework has recently gained more attention, 
following a 2012 Commission Communication on the Combined Effects of Chemicals (EC, 
2012). The communication required further work to be accomplished in order to reach a 
consistent approach to the assessment of priority mixtures across the different relevant 
pieces of EU legislation.  
After having reviewed the regulatory requirements, available guidance and approaches 
for the risk assessment of chemical mixtures (Kienzler et al., 2016b; Kienzler et al., 
2014), EURL ECVAM investigated the applicability of novel, non-animal tools and 
scientific methodologies in the assessment of combined effects of chemicals on humans 
and the environment. These tools and methods allow meaningful information on 
individual mixture components or whole mixtures to be derived. Since it is practically 
impossible to test all possible chemical mixtures experimentally, the application of smart 
strategies using new, alternative tools that rely less on in vivo testing and incorporate 
instead alternative experimental and computational tools is of particular importance in 
the context of chemical mixtures. EURL ECVAM has conducted a review of recent 
literature and has surveyed the experience of experts on the different approaches, such 
as the adverse outcome pathway (AOP) concept, in vitro methods, omics techniques, in 
silico approaches such as quantitative structure activity relationships (QSARs) and read-
across, toxicokinetic and dynamic energy budget (DEB) modelling, and on integrated 
approaches to testing and assessment (IATA) (Bopp et al., 2015). These can help 
achieve a more effective regulatory assessment and at the same time reduce the 
reliance on animal testing. Their main strengths lie in their integrated use and putting 
into context different aspects of the hazard from combined exposure to multiple 
chemicals. But in order to benefit from these tools in the hazard assessment of mixtures, 
more guidance on their use is needed to facilitate a more widespread application. 
In order to gain further insight into the issues linked to the risk assessment of chemical 
mixtures, EURL ECVAM further reviewed relevant case studies from the peer-reviewed 
literature (Bopp et al., 2016). Of the 21 recent case studies identified, some show a 
potential concern for several groups of chemicals for highly exposed or particularly 
vulnerable population groups. Parameters that could lead to an over- or underestimation 
of potential risks were identified. Case study results need to be interpreted with caution, 
considering the underlying assumptions, model parameters and related uncertainties. 
However, there is clear evidence that chemicals need to be further addressed not only in 
single substance risk assessments but also in mixture assessments that cover multiple 
chemical classes and legislative sectors. Furthermore, several issues hampering mixture 
risk assessments were identified. In order to perform a mixture risk assessment, the 
composition of the mixture in terms of chemical components and their concentrations 
need to be known, and information on their uptake and toxicity are required. Screening 
level assessments based on conservative assumptions are generally possible. However, 
refining such assessments to more realistic exposure scenarios is often not feasible due 
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to data gaps. In particular, relevant exposure and toxicity data as well as information on 
modes of action are often lacking. Future case studies on mixture risk assessment could 
fill the knowledge gaps identified. Such case studies could help by addressing differences 
between population groups, investigating different and emerging groups of substances, 
considering the relevance of interactions (i.e. synergisms), examining different 
approaches for the grouping of chemicals, and especially by investigating mixtures of 
potential concern that cross regulatory sectors. 
As international harmonisation is essential in this context, EURL ECVAM plays an active 
role in the OECD project on combined exposure (led by the OECD Task Force on Hazard 
Assessment in collaboration with the Task Force on Exposure Assessment) and supports 
the development of consistent assessment approaches for combined exposure to 
chemical mixtures at international level. 
5.6 Activities in the OECD Test Guideline Programme  
At the 28th meeting of the Working Group of National Coordinators of the OECD Test 
Guideline Programme (TGP) held at the OECD headquarters in Paris on 19th to 22nd April 
2016, 13 Test Guidelines were approved of which 4 were new TG and 9 were updated 
TG. Four TG out of the 13 were on in vitro methods, i.e. the in vitro skin sensitisation 
human Cell Line Activation Test (hCLAT); a Stably Transfected Human Androgen 
Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and 
Antagonist Activity; update of TG 431 for skin corrosion in vitro; update of Performance-
Based Test Guideline 455 for Stably Transfected Transactivation In Vitro Assays to 
Detect Estrogen Receptor Agonists and Antagonists to include the ER-CALUX test 
method. In addition TG 490 (approved in 2015) on In Vitro Mammalian Cell Gene 
Mutation Tests Using the Thymidine Kinase Gene for genetic toxicity testing was 
corrected.  
Seven Guidance documents or supporting documents were approved as well.  
The WNT agreed the new work plan that includes now twelve new projects, eight of 
which of relevance to the field of alternative methods/approaches. 
More information on the OECD TG programme can be found on the OECD website of the 
Test Guideline Programme45. 
The following chapters mainly focus on TGs for which the EC (through JRC-EURL ECVAM) 
had the lead or co-lead or carried out validation studies. However, some projects with 
relevance to the alternative field led by other Member Countries are also briefly 
described. Beside those, EURL ECVAM participated in numerous OECD expert groups and 
validation management groups and commented on several other draft TGs and GDs led 
by other OECD Member Countries.  
5.6.1 Development of an OECD Test Guideline on in vitro Fish Hepatic 
Metabolism  
The OECD project on the development of a new OECD TG on In vitro Fish Hepatic 
Metabolism (under the lead of USA and the EC represented by JRC - EURL ECVAM) aims 
at standardising two in vitro methods using rainbow trout S9 fraction (Johanning et al., 
2012) or cryopreserved rainbow trout hepatocytes (Fay et al., 2015) to determine in 
vitro fish intrinsic hepatic clearance rates. The project builds on work carried out within 
the framework of the ILSI HESI project "Bioaccumulation". ILSI HESI coordinated a 
multi-laboratory ring trial to assess the reliability, transferability, and predictive value of 
                                           
45 http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelate
ddocuments.htm 
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the two in vitro methods (2014-2016). Based on the results of the ring trial two draft 
OECD TGs are in preparation and it is planned to start consultation with WNT experts in 
2017. 
The fish intrinsic hepatic clearance rate derived with in vitro methods can be 
extrapolated to a whole-body metabolism rate constant. Inclusion of measured 
biotransformation rates enhances the reliability of models to estimate the 
Bioconcentration Factor (BCF; (Nichols et al., 2013; Laue et al., 2014)). The BCF is 
either predicted or measured (typically in fish, but if necessary, also in invertebrates).  
The bioconcentration potential of a chemical is important information that is required in 
many pieces of chemical legislation. It is used for hazard classification and for the 
assessment of persistent, bioaccumulative and toxic (PBT) substances. More reliable BCF 
prediction models have the potential to reduce uncertainty and thus avoiding 
unnecessary testing on fish.  
5.6.2 Update of OECD Guidance Document 23 on Aquatic Toxicity 
Testing of Difficult Substances and Mixtures 
This project initiated by the International Council on Animal Protection in OECD 
Programmes (ICAPO) and co-led by the EC- EURL ECVAM) addresses the use of solvents 
in aquatic toxicity tests on fish. When solvents are used, e.g. for the testing of poorly 
soluble chemicals, OECD test guidelines require two control groups - a water control and 
a solvent control. Part 1 of the project aims at updating OECD Guidance Document 23 on 
Aquatic Toxicity Testing of Difficult Substances and Mixtures (OECD, 2000) with 
advanced methodology for media preparation and exposure systems, and by that 
minimising the use of solvents. At the WNT meeting in 2016, OECD member countries 
agreed upon the complete revision of GD23 (under the lead of USA) in view of the many 
comments received on all sections of the document during the 1st WNT commenting 
round.  
Part 2 of the project aims at determining whether it is possible to use only one control, 
the solvent control, when solvents are used in aquatic toxicity tests on fish. A 
retrospective review of existing data generated according to OECD test guidelines in the 
presence of a solvent will be used to determine if the use of only one control would 
impact the outcome of the study. It is anticipated that a Detailed Review Paper (DRP) 
will be prepared. The project was approved in 2015 and included in the OECD work plan. 
5.6.3 Revision of OECD Guidance Document 126  
The project aims at updating OECD GD126, the threshold approach for acute fish toxicity 
(OECD, 2010), and integrate the fish embryo acute toxicity test (OECD TG 236, 2013b) 
into the step-wise approach for determining acute fish toxicity data. The project started 
in 2015 under the lead of Austria and ICAPO. 
5.6.4 Revision of OECD Test Guideline 203 
OECD TG203 fish acute toxicity test (OECD, 1992) determines the concentration of a 
chemical at which 50% of the fish die (LC50) and is one of the few guidelines still using 
death as an endpoint. The project (led by Switzerland and UK) aims at including the use 
of non-lethal endpoints (moribund state) to reduce the suffering of the fish.  
5.6.5 Critical Assessment of Technical Requirements in OECD Test 
Guidelines using Vertebrate Non-mammalian Species 
This new OECD project (led by UK) focuses on test guidelines using vertebrate (non-
mammalian) species (e.g. fish, amphibian, birds) for ecotoxicity testing and follows up 
on a recommendation of the OECD Fish toxicity testing framework (OECD, 2012a). It will 
investigate whether specified deviations from the technical requirements laid down in the 
TGs may have an impact on the outcome of the individual studies. Reducing the 
uncertainty of the potential impact on study outcomes may avoid unnecessary repetition 
of studies and animal use, respectively. 
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5.6.6 OECD Validation Studies with Transgenic Fish and Amphibian 
Models to Identify Endocrine Disruptors 
Within the OECD test guideline programme, France is leading two projects aiming at the 
validation of aquatic transgenic models, i.e. the EASZY and XETA assays. The EASZY 
assay is based on the use of transgenic cyp19a1b-GFP zebrafish embryos for detection 
of endocrine active substances acting through the estrogen pathway (Brion et al., 2012). 
The XETA (Xenopus Embryonic Thyroid Signalling Assay) allows the identification of 
endocrine active substances acting through the thyroid pathway. It uses transgenic 
ThβZIP-GFP Xenopus embryos where the GFP expression correlates with the level of 
expression of the ThβZIP gene, a direct thyroid hormone response gene and well 
characterised transcription factor involved in the control of amphibian metamorphosis 
(Fini et al., 2007). 
Both models have metabolic capacity and therefore have the potential of identifying 
substances requiring metabolic activation. 
5.6.7 OECD Test Guideline on the Human Cell Line Activation Test (h-
CLAT)  
The h-CLAT Test Guideline was approved by the WNT at its April meeting in 2016. The h-
CLAT method is proposed to address the third key event of the skin sensitisation AOP by 
quantifying changes in the expression of cell surface markers associated with the 
process of activation of monocytes and dendritic cells (i.e. cell surface markers CD86 
and CD54), in the human monocytic leukaemia cell line THP-1, following exposure to 
sensitisers (Ashikaga et al., 2006). The measured expression levels of CD86 and CD54 
cell surface markers are then used for supporting the discrimination between skin 
sensitisers and non-sensitisers.  
The h-CLAT method has been evaluated in an EURL ECVAM coordinated validation study 
and subsequent independent peer review by the EURL ECVAM Scientific Advisory 
Committee (ESAC). Considering all available evidence and input from regulators and 
stakeholders, the h-CLAT was recommended by EURL ECVAM (EURL ECVAM, 2015) to be 
used as part of an IATA to support the discrimination between sensitisers and non-
sensitisers for the purpose of hazard classification and labelling.  
 
5.6.8 Performance Based Test Guideline on CYP Induction assays 
The human cytochrome P450 (CYP) activity n-fold induction in vitro test method which 
describes the methodology to assess the potential of test chemicals to induce three 
cytochrome P450 (CYP) enzyme activities (CYP1A2, CYP2B6, and CYP3A subfamily) in 
two human-derived metabolically competent hepatic in vitro test systems has been 
successfully validated and peer reviewed (see EURL ECVAM status reports 2014 and 
2015, Zuang et al., 2014 and 2015). The two test systems are: the cryopreserved 
human primary hepatocytes (cryohep) and the cryopreserved human HepaRGTM 
(cryoHepaRGTM). An OECD Expert Group on Biotransformation Assays had been 
convened in May 2015 where the experts recognised the importance of developing in 
vitro metabolism OECD TGs based on CYP induction which could be used when 
establishing the hazard of both individual chemicals and mixtures. An OECD TG that 
would enable the induction to be determined in vitro using human hepatocytes was 
considered of benefit to all classes of chemicals. 
Additional discussions revealed however, that, while for the development of drugs 
targeted to humans, the use of three different donors of cryohep was the gold standard 
within the pharmaceutical regulations, for chemicals screening on the other hand, a 
higher throughput assay showing more experiment to experiment consistency, would be 
more valuable. Based on the validation data, the cryoHepaRGTM is less variable. 
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The expert group indeed considered the cryoHepaRGTM model more consistent and 
possible to be tailored for chemical screening needs (rather than drug design and drug 
metabolism).  
Considering the urgent need for TGs on in vitro metabolism, in terms of time frame for 
further evaluation of this methodology, the expert group considered that a PBTG was not 
appropriate at this point in time and suggested the development of a TG at short-term, 
ultimately a PBTG at medium-term, while keeping in mind AOP/IATA development at 
long-term. The expert group very much supported a TG on the cryoHepaRGTM model. 
Some experts offered to search for additional data on industrial chemicals generated 
with this test and also suggested to involve the WNT in this endeavour. At medium-stage 
a PBTG and an explanatory background review document (BRD) explaining the context 
of use of this type of PBTG could be prepared. Such a background document should 
address in particular the use purpose of a PBTG on CYP induction in a regulatory hazard 
characterisation and risk assessment context to generate wider understanding and 
appreciation of the value of information on the CYP inducing properties of a chemical. 
 
5.6.9 Integrated Approaches to Testing and Assessment of Non-
genotoxic Carcinogens  
Non-genotoxic carcinogens contribute to an increased cancer risk by a variety of 
mechanisms that are not yet included in international regulatory approaches. To address 
this need, an integrated approach to testing and assessment (IATA) of non-genotoxic 
carcinogens is beginning to be developed internationally under the auspices of the OECD. 
An expert working group has in fact been set up and has met for the first time in March 
2016 to examine the current international regulatory requirements and their limitations 
in respect to non-genotoxic carcinogenicity, and how an IATA could be developed to 
assist regulators in their assessment of non-genotoxic carcinogenicity. Moreover, the 
working group is tasked to review, describe and assess relevant in vitro assays with the 
aim of tentatively organising them into levels of testing, following the adverse outcome 
pathway format, such as that possible structure(s) of the future IATA(s) can be created. 
Some preliminary work to this activity has already been described in a publication of 
Jacobs and colleagues (Jacobs, 2016). 
 
5.6.10 Integrated Approaches to Testing and Assessment on Eye 
Irritation/Serious Eye Damage  
The assessment of the serious eye damage/eye irritation endpoint is a basic information 
requirement in international regulations for the classification and/or safety assessment 
of chemicals, pesticides, and medicines. Under some regulations (e.g., EU Cosmetics 
Regulation, REACH) this information is required to be generated without the use of 
animal tests. Since 2002, the OECD TG 405 on in vivo "acute eye irritation/corrosion" 
contains a supplement describing a sequential testing and evaluation strategy. This 
strategy recommends that, prior to undertaking the described in vivo test, a weight-of-
evidence analysis be performed on all existing relevant data. Where insufficient data are 
available, new data be developed through application of a sequential testing strategy, 
starting first with alternative methods, in order to avoid unnecessary testing in 
laboratory animals. Since the publication of the supplement in 2002, several in vitro 
methods for serious eye damage/eye irritation have been developed, validated and 
accepted by the OECD. Depending on country requirements and the results obtained 
with the OECD accepted methods (i.e., BCOP, ICE, FL, EpiOcular™ EIT and STE), they 
may in many cases satisfy all information requirements for serious eye damage/eye 
irritation. In addition, non-standards methods (i.e., not yet validated and/or accepted by 
OECD) may provide further information (e.g., persistence vs. reversibility of effects, 
direct identification of Category 2 chemicals) that could contribute to the full 
replacement of the in vivo rabbit eye test. Although the suitability of such data for 
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regulatory purposes needs to be judged case by case, they should be considered before 
conducting animal studies. For these reasons, guidance in relation to the use and 
generation of data for serious eye damage/eye irritation requires an update. The EC 
represented by JRC-EURL ECVAM and the US EPA are thus jointly leading the 
development of a Guidance Document on an IATA for serious eye damage/eye irritation 
at the OECD. The objective is to provide guidance on the possible use and usefulness of 
individual test methods and on how to best combine them to reach a scientifically sound 
conclusion in an effective way, at the same time minimising animal testing to the extent 
possible. The project proposed by the EC and the U.S. EPA was approved by the WNT in 
April 2015 and a first draft of the Guidance Document was circulated to the WNT for 
commenting on the 18th of March 2016. An amended version of the document 
addressing the WNT comments will be discussed by the OECD Expert Group on eye 
irritation during a meeting at the OECD headquarters on 3-4 November 2016 and will be 
recirculate to the WNT before the end of the year for another commenting round. The 
final document is expected to be submitted for approval by the WNT in April 2017. 
 
5.6.11 Draft OECD Guidance Document on Good In Vitro Method 
Practices for the Development and Implementation of In Vitro 
Methods for Regulatory Use in Human Safety Assessment  
A guidance document on Good In Vitro Method Practices (GIVIMP) for the development 
and implementation of in vitro methods for regulatory use in human safety assessment 
was identified as a high priority requirement. Such a GD aims at reducing the 
uncertainties in cell and tissue-based in vitro method derived predictions by applying all 
necessary good scientific, technical and quality practices from in vitro method 
development to in vitro method implementation for regulatory use. The draft GIVIMP 
guidance is coordinated by EURL ECVAM and it was accepted on the work plan of the 
OECD test guideline programme in April 2015 as a joint activity between the Working 
Group on Good Laboratory Practice and the Working Group of the National Coordinators 
of the Test Guideline Programme (WNT). During the first drafting stage, expert input 
was received from European regulatory agencies [i.e. the European Food Safety 
Authority (EFSA), the European Medicine Agency (EMA), the European Chemicals Agency 
(ECHA)], the European Union Network of Laboratories for the Validation of Alternative 
Methods (EU-NETVAL), the EU and OECD Working Groups on GLP, Three Rs Centres, a 
regulatory agency (RIVM), from scientists of large industries and SMEs and from 
international scientists with expertise in stem cells, cell biology, GLP and in vitro 
methods. 
The draft document was sent to the members of the EU-NETVAL (37 laboratories across 
Europe), to the experts of the Working Group on Good Laboratory Practice and the WNT 
in September and October 2016, respectively. 
The Guidance aims to further facilitate the application of the OECD Mutual Acceptance of 
Data agreement for data generated by in vitro methods and as such contribute to 
avoidance of unnecessary additional testing. It describes the areas related to in vitro 
method development, standardisation, harmonisation and international acceptance that 
would benefit from more detailed scientific, technical and quality guidance. 
This guidance is not intended to duplicate or replace existing OECD Guidance Documents 
but rather to complement them by addressing specific gaps and collecting available 
references and information on best scientific, technical and quality practices in one 
document. The document has been discussed at the EU NETVAL meeting on 10th 
October 2016.  
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5.6.12 OECD Guidance Document on Considerations for Waiving or 
Bridging of Mammalian Acute Toxicity Tests  
In November 2014 an OECD expert group on acute mammalian toxicity was established 
and EURL ECVAM was nominated as member of this group. The OECD project, that was 
included in the OECD Test Guidelines programme in 2014, was initiated by USA and 
Canada and it was based on guidance developed for pesticides (U.S. EPA 2012, Health 
Canada 2013).  
The first draft of the guidance was circulated for review late in 2014 and based on the 
feedback received a revised draft was circulated to the expert group in May 2015 for 
another review/comment round. Two conference call meetings were then organised by 
the OECD Secretariat with the Expert group and lead countries to address and discuss 
the 55 comments received and the responses drafted by the lead countries. Most of 
EURL ECVAM's comments were aimed at clarifying 1) when a particular in vivo study 
could be waived based on skin corrosivity; 2) when the waiver of an acute oral toxicity 
test can be considered if the oral LD50 of the test material is predicted to be greater than 
2000 mg/kg bw using alternative methods; 3) that the titles and text of the sections on 
dermal and eye irritation are aligned with the relevant ECHA guidance documents.  
The guidance document introduces several considerations where a mammalian acute 
toxicity study may be waived. The criteria outlined in the document are applicable to 
mammalian acute toxicity via the oral, dermal and inhalation route, eye and skin 
irritation and skin sensitisation. Although the document is intended for the assessment of 
pesticides, the principles included can be extended to the assessment of other 
chemicals, formulations and biological materials. The disclaimer included in the guidance 
document encourage regulatory jurisdictions to the use of the approaches outlined 
herein as part of the weight of evidence in determining the need for a mammalian acute 
toxicity study and appropriate classification and/or labelling. 
The Guidance document that was approved at the 28th meeting of the Working Group of 
the National Coordinators for the Test Guidelines Programme, has been recently 
published (OECD, 2016i) after being declassified by the Joint Meeting of the Chemicals 
Committee and the Working Party on Chemicals, Pesticides and Biotechnology in July 
2016. 
 
5.6.13 Proposal for the Deletion of Test Guideline on the Rodent 
Dominant Lethal Test (TG 478) 
A revised TG 478 on Rodent Dominant Lethal Test was adopted in July 2015. Although it 
has been recognised that the revised TG had undergone significant improvements, 
several factors pointed to the potential merit of deleting this TG in the near future. These 
factors include: scientific limitations concerning the limited specificity and sensitivity of 
the test; the use of a huge number of animals; the fact that the test is labour-intensive 
and costly; the lack of laboratories that have experience in the conduct of this test; the 
availability of other tests to assess the same endpoint (i.e. germ cell genotoxicity). The 
test is rarely performed around the world and this is reflected by the fact that the 
references reported in TG 478 are from mid-70s to mid-90s, indicating the lack of recent 
reliable data. Literature search showed only a few more recent research publications of 
rather questionable quality. In addition, TG 478 already underlined that "due to its 
limitations and the use of a large number of animals, this assay is not intended for use 
as a primary method, but rather as a supplemental test method which can only be used 
when there is no alternative for regulatory requirements." Moreover, the summary 
record of the 27th WNT meeting stated "When timely for countries to re-open the 
discussion of the deletion of TG 478, a proposal via a Standard Project Submission Form 
(SPSF) could be submitted via a National Coordinator." 
For the reasons listed above and after consultation with European Agencies (i.e. EMA, 
ECHA and EFSA), the EC considered that it was timely to submit an SPSF to propose TG 
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478 deletion. Although most of the EU Member States were in favour, no consensus was 
reached for its deletion at the 28th WNT meeting in 2016. 
 
5.6.14 Workshop on Developmental Neurotoxicity  
The initiative to organise a stakeholder workshop (18-19 October 2016) on an integrated 
testing strategy for developmental neurotoxicity (DNT) has been undertaken in 
collaboration with the EFSA secretariat, the OECD secretariat and the JRC/EURL ECVAM. 
The workshop's intended objective is to develop consensus on which testing battery of 
alternative DNT methods could be applied right now in a fit-for-purpose manner for 
chemical screening for prioritisation, or hazard identification for specific chemical risk 
assessment and which could lead to the development of IATA (Integrated Approaches to 
Testing and Assessment). 
The programme of the workshop covers the perspectives of regulatory bodies, industry 
and academia on DNT testing strategies based on alternative approaches. During the 
workshop the JRC/EURL ECVAM will present its strategic aims, addressing the utility of 
non-animal approaches applied to the assessment of DNT for different regulatory 
purposes. 
The intention of EFSA is to follow up the event with the initiation of an EFSA working 
group for the preparation of a scientific opinion on an integrated testing strategy for the 
identification and evaluation of hazards associated with DNT, for substances such as 
pesticide active substances and their metabolites. The publication of a report presenting 
the main outcomes of the workshop is envisaged. 
5.7 Contributions to the OECD Adverse Outcome Pathway 
Development Programme 
An Adverse Outcome Pathway (AOP) describes a logical sequence of causally linked 
events at different levels of biological organisation, which follows exposure to a chemical 
and leads to an adverse health effect in humans or wildlife. AOPs are the central element 
of a toxicological knowledge framework, promoted by member countries through OECD, 
built to support chemical risk assessment based on mechanistic reasoning.  
The EC (through JRC/EURL ECVAM) has shown commitment to the goals of the OECD 
programme on Adverse Outcome Pathways in many ways, including co-chairing with US 
EPA the Expert Advisory Group on Molecular Screening and Toxicogenomics (EAGMST) 
tasked with implementing the programme, contributing to the development of guidance 
on principles and best practices of AOP development, working in close collaboration with 
US EPA, US Army Corps of Engineers – Engineering, Research and Development Center 
(ERDC) and OECD on the development of the AOP Knowledge Base and its various 
components (see 6.4) developing and delivering training courses (see 6.5) and, not 
least, the actual development of a number of AOPs including entering them into the AOP 
Wiki. The first AOPs to go through the process of internal and external peer review 
within the OECD were finalised and published on the OECD website in August 201646. Of 
these first five AOPs, three were developed by EURL ECVAM.  
These were: 
 Protein Alkylation leading to Liver Fibrosis (Landesmann B, 2016) 47  
 Binding of agonists to ionotropic glutamate receptors in adult brain causes 
excitotoxicity that mediates neuronal cell death, contributing to learning and 
memory impairment48 
                                           
46  http://www.oecd-ilibrary.org/environment/oecd-series-on-adverse-outcome-pathways 
_2415170x;jsessionid=20oo8q54271qt.x-oecd-live-03 
47 https://aopwiki.org/wiki/index.php/Aop:38 
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 Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) 
during brain development induces impairment of learning and memory abilities49 
In addition EURL ECVAM also introduced the OECD AOP for skin sensitisation, which had 
been drafted and agreed before the creation of the AOP Wiki, into the Wiki: 
 Covalent Protein binding leading to Skin Sensitisation50  
  
A number of other AOPs authored by EURL ECVAM are in different stages of development 
and review as follows:- 
 Binding of inhibitor to the Complex I of mitochondrial ETC leads to motor deficit 
of Parkinson's disease (in collaboration with EFSA) 
 PPAR activation leading to impaired fertility in adult males 
 PPARγ activation leading to impaired fertility in adult females 
 Sodium Iodide Symporter (NIS) inhibition and subsequent adverse 
neurodevelopmental outcomes in mammals 
 Lysosomal damage (caused by nanoparticles) leading to liver inflammation 
EURL ECVAM has undertaken the first steps in applying the AOP framework to 
neurodevelopmental toxicity evaluation (Bal-Price et al., 2016) and identified potential 
AOPs relevant to both developmental and adult neurotoxic outcomes (Bal-Price et al., 
2015; Bal-Price et al., 2016). 
The AOPs elaborated to date are mainly qualitative pathway descriptions, and further 
research efforts are necessary to develop a more-precise characterisation of the dynamic 
relationships between key events in quantitative terms. In an effort to move forward on 
this aspect, EURL ECVAM hosted a workshop in September 2015 on AOP-Informed 
Predictive Modelling Approaches for Regulatory Toxicology to discuss how the systematic 
organisation of knowledge into AOP frameworks can inform and help direct the design 
and development of computational prediction models that can further enhance the utility 
of mechanistic and in silico data for chemical safety assessment. The workshop report 
(in press) lays out a vision for how AOPs might be used to facilitate development of 
computational prediction models needed to support the next generation of chemical 
safety assessment. 
Even though the level of information currently available is not sufficient to perform a 
comprehensive risk assessment, a well-described AOP may still provide useful 
information for many purposes, such as priority setting for further testing, hazard 
identification, read-across for categorisation of chemicals or contributing to the 
development of integrated approaches to testing and assessment (IATA). It is 
anticipated that all the work on AOPs will help towards refinement, reduction and 
ultimately replacement of conventional in vivo animal testing. 
 
 
 
                                                                                                                                   
48 https://aopwiki.org/wiki/index.php/Aop:48  
49 https://aopwiki.org/wiki/index.php/Aop:13  
50 https://aopwiki.org/wiki/index.php/Aop:40  
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5.8 Promoting Regulatory Acceptance in the Frame of EMA: JEG 
3Rs  
The European Medicines Agency (EMA) decided in 2010 to establish an expert group, 
JEG 3Rs51, which should provide advice and recommendations to the Committee for 
Medicinal Products for Veterinary Use (CVMP) and Committee for Medicinal Products for 
Human Use (CHMP) on all matters relating to the use of animals and the application of 
the Three Rs in the testing of medicines for regulatory purposes. Members of the JEG 
3Rs are European experts of the CVMP and CHMP working parties for which animal 
testing is relevant, other named Three Rs experts, and representatives from EDQM and 
the European Commission (e.g. EURL ECVAM). JEG 3Rs recently published a draft 
Reflection paper providing an overview of the current regulatory testing requirements for 
veterinary medicinal products and opportunities for implementation of the 3Rs52 and a 
comparable document is in preparation for human pharmaceuticals. Further ongoing 
work relates to compliance checking of EMA guidelines with Three Rs principles and 
proposals for revision, the development of guidance on the acceptance of Three Rs 
testing approaches53 in pharmaceuticals testing; Three Rs issues related to batch release 
testing of vaccines as well as guidance on the use of transferring quality control methods 
validated in collaborative trials to a product/laboratory specific context54.  
5.9 Activities of EPAA to Promote the Regulatory Acceptance of 
Alternative Methods  
The partnership runs a number of projects and organises or financially supports 
workshops and conferences which aim at promoting the regulatory acceptance of 
alternative methods and approaches. 
5.9.1 Waiving of Two-year Carcinogenicity Studies  
The University of Wageningen has collaborated with the Dutch Medicines Evaluation 
Board to compile and analyse a database on active pharmaceutical ingredients. The aim 
was to confirm and expand previous investigations by Sistare et al., 2011, to identify 
opportunities for waiving the two-years carcinogenicity studies based on in vitro 
genotoxicity testing and the results of (sub-)chronic toxicity studies. Moreover, the 
combination of the histopathological approach as proposed by Sistare et al., 2011 with 
the pharmacological approach as presented in a recent paper of van der Laan et al., 
2016 is investigated. A manuscript describing the outcome of this project has been 
submitted.  
5.9.2 Acute toxicity  
A data mining exercise was initiated in 2015 in close collaboration with the UK National 
Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
                                           
51 JEG 3Rs = The Joint Committee for Medicinal Products for Veterinary Use/Committee 
for Medicinal Products for Human Use Ad-hoc Expert Group on the Application of the 3Rs 
in Regulatory Testing of Medicinal Products http://www.ema.europa.eu/ema/ 
index.jsp?curl=pages/contacts/CVMP/people_listing_000094.jsp&mid=WC0b01ac05803a
9d6d  
52 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/0
4/WC500205609.pdf  
53 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/1
0/WC500174977.pdf 
54 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/0
7/WC500211432.pdf 
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and the UK Chemicals Regulation Directorate (CRD) to enable the identification of clinical 
signs predictive of mortality (EPAA, 2015). The whole exercise was delayed due to the 
large number of studies that need to be screened, which was larger than originally 
expected. Nevertheless, the team is currently finalising the screening, data copying and 
data coding of a large enough number of studies to allow a robust statistical analysis of 
data to identify predictive clinical signs of mortality. 
The ultimate aim is to build a decision framework document to replace animals in acute 
toxicity testing and in those cases where animal usage cannot be avoided, to substitute 
clinical signs predictive of mortality at higher dose levels and thereby replace mortality 
as the principal endpoint. 
Discussions were held between members of the EPAA project and ECHA to ensure that 
the outcomes of this scientific data analysis were relevant in the context of the update of 
ECHA guidance on acute toxicity and the 2018 REACH registration deadline. 
5.9.3 The Vaccines Consistency Approach 
In order to facilitate the introduction of the consistency approach for the quality control 
of established human and veterinary vaccines, EPAA has initiated a project aimed at 
developing and validating non-animal methods with the support of stakeholders from 
academia, regulators, Official Medicines Control Laboratories (OMCLs), EDQM, European 
Commission and vaccine manufacturers. A recent publication summarises the work 
carried out within the four priority vaccines/vaccine groups (diphtheria/tetanus/acellular 
pertussis vaccines; human rabies vaccines; veterinary rabies vaccines; clostridial 
vaccines) defined at the start of the project in 2011 (De Mattia et al., 2011).  
EPAA decided in 2016 to close the overarching Vaccines Consistency Approach project 
and continue the two sub-projects on clostridial vaccines (see 5.9.4) and human rabies 
vaccines (see 5.9.5) as individual projects. The work on implementation of the 
consistency approach, in general, and in particular for diphtheria, tetanus, acellular 
pertussis vaccines and veterinary rabies vaccines will be continued in the VAC2VAC 
research project launched in March 2016 (see 2.6.1). 
5.9.4 Clostridial vaccine project 
The clostridial vaccines group evaluated Vero cell based assays to replace the Minimum 
Lethal Dose and Total Combining Power assays required for in-process control of 
Clostridium septicum vaccines. The collaborative study was carried out in collaboration 
with the EDQM BSP and the results of BSP130 were discussed with the study participants 
at a satellite workshop on 15-16 September 2015. The results show that the in vitro 
assays are repeatable and reproducible and that there is excellent overall concordance 
with the mouse tests (Sinitskaya et al., 2016). However, in order to fully exploit the 
advantage of the Vero cell assays, further work is needed. A follow-up study started in 
2016 aiming at the further optimisation of the Vero cell assays to increase their 
sensitivity and accuracy.  
Adaptations of the Vero cell assays to other clostridial vaccines will be evaluated in the 
VAC2VAC project.  
5.9.5 Human rabies vaccine project 
Based on the outcome of discussions held at an EPAA workshop in 2012, the EPAA 
human rabies vaccines group organised a collaborative study to identify the most 
suitable ELISA for quantitation of glycoprotein-G in rabies vaccines and possible 
replacement of the current in vivo test for potency testing of human rabies vaccines. 
Vaccine samples of different origin and composition were tested with three different 
ELISAs currently in use by manufacturers and control authorities. The results of the 
study and possible follow up have been discussed at a workshop in May 2015 (a paper is 
in preparation). One out of the three ELISAs correctly quantified the antigen content of 
all vaccine samples (including degraded samples). After additional work carried out 
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during 2016, this ELISA was presented to and accepted by the EDQM BSP for full 
validation. 
5.9.6 Harmonisation on Biologicals  
The EPAA project aims at progressing harmonisation of requirements for batch testing of 
vaccines and other biological products at a global level. Due to evident differences in the 
current regional requirements, manufacturers may need to carry out animal tests which 
are no longer required in Europe, if they want to market their products outside of 
Europe. EURL ECVAM is a member of the project team. 
During 2013-2014, key requirements and differences in the various regions were 
mapped and possible areas for harmonisation defined. As a follow-up, EPAA convened an 
international workshop (15-16 September 2015) with representatives from regulatory 
bodies and manufacturers to discuss steps towards deletion of general safety tests and 
to identify means towards implementation of in vitro methods for potency testing of 
human and veterinary vaccines. The workshop report Modern science for better quality 
control of medicinal products: Towards global harmonisation of 3Rs in biologicals55 is 
available on the EPAA website56. The major recommendation – agreed by all participants 
– is the deletion of general safety tests, e.g. abnormal toxicity test, target animal batch 
safety, from regulatory requirements at a global level. Nowadays, these tests lack 
scientific relevance and their omission does not compromise the safety of vaccines, or 
any other pharmaceutical, since more adequate quality control measures are in place. 
The project team is following up the recommendations in collaboration with workshop 
participants and relevant stakeholders. 
5.9.7 Optimised Evaluation of Skin Sensitisation  
In December 2015, the EPAA skin sensitisation team started a new project aimed at 
comparing the performance of in vitro skin sensitisation methods based on 3D-epidermis 
to predict a set of "difficult" reference chemicals. The ultimate purpose of this project is 
to explore whether methods using reconstituted human epidermis as a model system 
can overcome some of the limitations of the OECD adopted in chemico / in vitro tests. 
Such limitations are mainly related to difficulties in testing highly hydrophobic molecules 
including mixtures and to accurately predict potency, potential reasons being the fact 
that application to cells cultured in an aqueous-based medium differs from topical 
application to the skin as is the case in the clinical situation or animal test, and 
differences in metabolic profiles of cultured cells versus in vivo cells. 
5.10 ILSI HESI activities: Framework for Intelligent Non-Animal 
Alternative Methods for Safety Assessment  
The Health and Environmental Sciences Institute (ILSI HESI) has created a multi-sector 
forum to develop criteria to develop confidence in the use and acceptance of non-animal 
methods to support regulatory decisions. The objective of the group is to determine 
criteria to be used in assessing fitness-for-purpose methods and approaches for 
decision-making, provide general guidance for establishing sufficient confidence in non-
animal methods and ensure peer engagement and transparency to assess the 
acceptability of the group’s proposals. Three working groups have been established 
covering the following issues: 1) performance characterisation; 2) model predictive 
performance; and 3) utilisation. The final outcome of this activity will be the 
development of a white paper/publication that reflects the consensus of the group.  
                                           
55 https://circabc.europa.eu/sd/a/4a081e45-f19f-47f7-8d8d-65f4f10fccff/ihb%20sept 
%202015%20report.pdf  
56 http://ec.europa.eu/growth/sectors/chemicals/epaa/ 
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5.11 Standard documentation of exposure models – MERLIN-Expo 
case study CEN Workshop Agreement  
An important step in facilitating the acceptance and use of a computational model is the 
development of comprehensive and structured documentation. This is particularly 
challenging for environmental and/or human exposure models that aim to establish 
quantitative relationships between personal exposure levels and their determinants. 
Exposure models conceptually simulate the transport and fate of a contaminant from the 
source to the receptor and may then involve a large set of entities (e.g. all the 
environmental media the contaminants may pass through). Such complex models are 
difficult to describe in a comprehensive, unambiguous and accessible way. To address 
this difficulty, EURL ECVAM participated in a CEN (European Committee for 
Standardisation) initiative57,58 that aimed to agree on minimum requirements for the 
amount and type of information to be provided on exposure models documentation along 
with guidelines for the structure and presentation of the information (Altenpohl et al., in 
press; Ciffroy et al., 2016). 
5.12 Analysis of Carcinogenicity Testing for Regulatory Purposes 
in the European Union 
The approaches for evaluating the carcinogenic potential of substances, including 
whether carcinogenicity studies should be conducted, differ substantially across sectors. 
Despite variations in testing schemes, the two-year bioassay study in rodents represents 
the standard element across all sectors. The validity of the two-year bioassay has 
however been questioned in the last decade. Uncertainty is associated with the 
extrapolation of data from rodents to humans. Furthermore, these studies are extremely 
time and resource-consuming and the high animal burden has raised ethical concerns. 
For all these reasons, there is a strong demand for alternative strategies and methods in 
this area. The development of new in vitro methods for carcinogenicity testing, however, 
has progressed slowly and those available are far from being accepted for regulatory 
decision making, especially when evaluating the carcinogenicity of non-genotoxic 
chemicals or specific classes of compounds such as biologicals and nanomaterials. 
In this context, EURL ECVAM has carried out an analysis of carcinogenicity testing across 
sectors in the European Union (Madia et al., 2016). This consisted of a systematic review 
of the different regulatory testing schemes; an analysis of the number of animals used 
per sector and an estimation of the number of carcinogenicity and genotoxicity studies 
conducted or waived in respect of the number of substances authorised per sector per 
year. Moreover, a review of the types of justification for waiving the two-year bioassay 
has been conducted. Results from this analysis will provide context for initiatives aimed 
at: 1) reducing the need for animal use where animal testing is still a requirement; 2) 
ensuring an adequate hazard identification and characterisation in sectors where animal 
use is banned or limited; and 3) identifying areas where existing methods are not 
suitable.   
5.13 Strategic Aims for Improving Developmental Neurotoxicity 
(DNT) testing for Different Regulatory Purposes using non-
animal methods  
Currently there is a recognised need for neurotoxicity evaluation at the regulatory level 
(Bal-Price et al., 2012). However, systematic testing for DNT is not a mandatory 
requirement in Europe for pesticides or chemical safety assessments and it is performed 
only as higher tiered tests triggered by, and based on, structure activity relationships or 
                                           
57 http://cordis.europa.eu/news/rcn/128194_en.html  
58 https://www.cen.eu/work/areas/chemical/Pages/WS-MerlinExpo.aspx  
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evidence of neurotoxicity in standard systemic adult, developmental or reproduction 
studies (Makris et al., 2009; Bal-Price et al., 2010 and 2012).  
The OECD Test Guideline for DNT evaluation (OECD, 2007b; TG 426) is entirely based on 
the use of animal tests that are centered on neurobehavioral evaluation of cognitive, 
sensory and motor functions accompanied by morphometric and histopathological 
studies. This in vivo based guideline is very resource intensive in terms of animals, time 
and overall costs. Therefore, there is the pressing need for developing alternative 
methodologies that can more rapidly and cost-effectively screen large numbers of 
chemicals for their potential to cause DNT. 
Based on an analysis of different regulatory scenarios, EURL ECVAM is considering a 
variety of possible approaches addressing the utility of non-animal approaches for DNT 
assessment, such as providing supplementary information on DNT to support screening, 
priority setting and hazard assessment, as well as supporting the development and 
evaluation of Integrated Approaches to Testing and Assessment (IATA), including 
considerations relevant for cumulative risk assessment (CRA). 
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6 Dissemination of Information on Alternatives 
6.1 Second Meeting of European 3Rs Centres  
Since 2015, EURL ECVAM has hosted two meetings with 3Rs Centres from across the EU, 
including EURL ECVAM. These centres focus on advancing the Reduction, Replacement 
and Refinement (Three Rs) of animal use for scientific purposes, through a variety of 
organisations and activities. Whilst the expertise within the centres may vary, shared 
priorities have been identified and explored as a means of achieving impact in the Three 
Rs. These priorities include:  
 Efforts to reduce animal use in biomedical research 
 Communication and dissemination 
 Promoting the use of alternative methods/models as biotechnological resources 
 Education and training 
 Validation towards regulatory acceptance 
 Research initiatives supported by 3Rs Centres 
The second meeting was held from May 31st to June 1st 2016 to explore these common 
interests further. Each organisation provided updates on their activities since the last 
meeting in 2015, as well as specific updates on ventures to enhance knowledge sharing 
such as Norecopa's new website59 and search engine, Johns Hopkins University Center 
for Alternatives to Animal Testing (CAAT) and CAAT-Europe's CAAT Academy60 and the 
Education and Training Platform for Laboratory Animal Science (ETPLAS61).  
A proposal put forward during the meeting was for the 3Rs Centres to become hubs of 
information to assist with a well-established knowledge chain. Each of the 3Rs Centres 
specialise in different elements and could formulate a network of 3Rs Centres of 
excellence to progress knowledge flow. Education and training was highlighted as an 
area which requires better coordination and 3Rs Centres could play a very important role 
here. All centres consider this to be a highly important aspect of their functions. As such, 
there is a large range of educational and training activities offered by the centres. These 
include producing teaching materials for schools, hosting large events and workshops 
and providing practical laboratory based training for professional scientists and 
technicians. The Three Rs focus of the training also varies depending on the specific 
competences of the centre. The opportunities for sharing expertise and materials are rich 
and need to be explored further.  
The summary record of the meeting will be made public on EURL ECVAM's website. 
6.2 EURL ECVAM Databases  
6.2.1 In vitro methods: DB-ALM - EURL ECVAM’s DataBase service on 
ALternative Methods to animal experimentation  
The DB-ALM62 provides ready-to-use and evaluated information about the application 
and development status of advanced and alternative methods in a standardised manner. 
Information at various level of detail is provided and defined according to pre-
determined criteria for data content by experts in the field (Table 6.1). Current focus is 
given to in vitro methods and non-experimental approaches used for safety assessments 
                                           
59 https://norecopa.no/  
60 http://www.caat-academy.org/  
61 http://www.etplas.eu/index.php?id=4325  
62 https://ecvam-dbalm.jrc.ec.europa.eu  
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of chemicals and/or formulations, but also includes methods for testing drugs or 
biologicals or for research purposes.  
Since 2015, the DB-ALM Method Summary data sector provides a harmonised framework 
for adequately describing alternative methods in an OECD accepted format63 
Table 6.1 The online information content originates from research projects, validation studies or individual 
submissions and covers as of September 2016: 
Information Sector 
Number of 
Documents 
Topic Summaries 5 
Method Summaries 178 
Protocols 157 
Method Evaluations, EU projects, 
Validation studies 
90 
Test Results (individual investigations) 9128 
Contacts to People active in the field 
of alternative methods 
93 
Bibliographic References 7003 
 
Growing interest in the DB-ALM was observed amounting to a total of nearly 5,000 
registrations from 82 countries with 499 new in 2015 being the fourth highest since its 
existence. The usage increased by 29% compared to the year before with over 40,000 
accesses to the website contents. The DB-ALM is referenced in formal OECD documents; 
scientific books and cited in scientific articles. The European Chemicals Agency (ECHA) 
suggests the DB-ALM as useful information source and the OECD recommended it for the 
storage and dissemination of non-guideline in vitro test methods.  
Further information can be obtained from the DB-ALM Progress Report 2014-201664. 
6.2.2 In silico methods: QSAR Model Database 
The JRC QSAR Model Database65 is a freely accessible web application that enables users 
to submit, publish, and search for peer-reviewed summary descriptions of QSAR Models. 
An internationally accepted format is used, known as the QMRF (QSAR Model Reporting 
Formats) to ensure the provision of comprehensive and consistent information. 
Developers and users of QSAR models can submit to the dedicated mailbox information 
on QSARs by using a downloadable QMRF editor which is reviewed for adequacy and 
completeness by the JRC-EURL ECVAM before publishing it through the JRC database. 
Properly documented QSAR Models are provided as robust summaries including results 
of any validation studies. However, inclusion of the model does not imply acceptance or 
endorsement by the JRC or the EC, and responsibility for use of the models lies with the 
end-users. 
                                           
63 OECD Guidance Document N◦211 for describing non-guideline in vitro test methods 
64 Access to the DB-ALM Report 2014-2016: 
http://publications.jrc.ec.europa.eu/repository/handle/JRC102254 
65 http://qsardb.jrc.ec.europa.eu 
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At the time of writing (July 2016), the online information content of JRC QSAR Model 
Database covers 109 QSAR Model Descriptions grouped according to OECD defined 
(regulatory) endpoints as indicated in Figure 6.1 out of which 39 QSAR Reports were 
published during the past 2 years. A progress report summarising the activities of the 
QSAR model database during 2014-2016 can be made available on request 
(JRC102362). 
 
 
Figure 6.1 QSAR Model Database Online Information Content 
As an indication of usage, in July 2016 (last update 28 July), the JRC QSAR Model 
database had a total of 435 visitors (354 unique), with an average of 16.0 per day (13.1 
unique). 
The public users worldwide originate from Poland, United Kingdom, Italy, Greece, 
Switzerland, Japan, India, United States of America, Colombia and Mexico.  
Period Total Visitors 
Visitors per 
Day 
Unique Visitors Unique Ratio 
Nov-14 
 
Jul-16 
99 
 
435 
3.3 
 
16 
62 
 
354 
63% 
 
81% 
Figure 6.2 QSAR Model Database Visitors (extract)
66
 
 
                                           
66 http://stats.jrc.cec.eu.int/?config=qsardb.jrc.it&year=2016&month=7&view=all 
months.all&lang=en-gb 
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6.2.3 Tracking System for Alternative Test Methods towards Regulatory 
acceptance (TSAR)  
TSAR67 serves to track progress of an alternative method, in a transparent manner, from 
proposal for validation through to its final adoption by its inclusion into the regulatory 
framework (EU, OECD and related standards). The currently developed revised TSAR 
version will also cover the needs of the individual partners of EURL ECVAM participating 
in the International Collaboration on Alternative Testing Methods (ICATM). In this way an 
overall view of the methods under evaluation by all international validation centres is 
provided from one access point. In order to be able to best cover all potential needs, 
more time has been invested in the project, creating a first beta version that has now 
technically been finalised. EURL ECVAM is currently in the process of compiling and 
reviewing the information content to be included in the first release. It is planned to 
present TSAR to its ICATM partners in October 2016 before TSAR will finally be released 
to the general public. 
6.3 Information Retrieval Guidance: EURL ECVAM Search Guide 
The EURL ECVAM Search Guide (first published in 2012 with a re-edition in 2013) 
continues to encounter success in and outside Europe and is also applied in America, 
with particular emphasis on South America, used as a resource for higher education in 
academic institutions in life sciences and by national authorities for scientific project 
evaluations that might involve animal use. It has now entered the Asian market where it 
was translated and re-published as a handbook and E-book in Korean. A Portuguese 
version is under development together with Brazilian Authorities within the framework of 
International Cooperation on Alternative Test Methods (ICATM).  
The EURL ECVAM Search Guide68 has specifically been developed to inform and support 
untrained database users in finding high quality information on relevant alternative 
methods and strategies from the large amount of available information resources in an 
easy, yet systematic, and efficient way during project preparations in biomedical 
sciences. 
6.4 Update on the Adverse Outcome Pathway Knowledge Base 
(AOP-KB)  
AOPs are the central element of a toxicological knowledge framework being built to 
support chemical risk assessment based on mechanistic reasoning (see 5.7). To enable 
the scientific community to share, develop and discuss their AOP-related knowledge in 
one central location, the OECD has – in parallel to the instigation of the overall AOP 
initiative – started the Adverse Outcome Pathway Knowledge Base (AOP-KB) project. 
Within this project EURL ECVAM contributes ICT design and analysis know how and co-
manages the project together with the US-EPA.  AOP-KB will consist of several modules, 
each tailored to specific needs; a module titled e.AOP.Portal will be the uniform search 
interface to retrieve AOPs from all other modules; the data interchange format to be 
used between the AOP-KB modules, named AOP-XML, was developed by EURL ECVAM. 
The first AOP-KB module available to the public is the AOP-KB Wiki, a system that 
organises, via crowd-sourcing, the available knowledge and published research into a 
verbal description of individual pathways, via a user friendly Wiki interface. Controlled-
vocabulary drop-down lists from which to select methods, actions, biological objects, life 
stages, species etc. related to the AOP simplify the entry of standardised information. In 
2015 and early 2016, the introduction of ontologies to further harmonise the naming of 
                                           
67 TSAR table on test submissions: https://eurl-ecvam.jrc.ec.europa.eu/test-submission 
68 http://bookshop.europa.eu/en/the-eurl-ecvam-search-guide-pbLBN124391/ 
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AOP objects was discussed and will be implemented in the AOP-KB Wiki in the second 
half of 2016. 
The introduction of the AOP concept into the area of chemical risk assessment is a major 
milestone towards the goal of identifying, assessing and ultimately accepting alternatives 
to animal tests for regulatory purposes. Without the AOP-KB tool, the AOP concept would 
remain a theoretical idea without any real-life impact. By facilitating the collection and 
also discussion of AOP-related information, the AOP-KB anchors this novel concept firmly 
in the scientific and regulatory environments, which is a prerequisite for a world with 
less animal testing. The new concept of Integrated Approaches to Testing and 
Assessment (IATA) will profit from the AOP concept as it informs scientists and 
regulators about the biology behind a chemical's mode of action. 
6.5 AOP Training Activities 
EURL ECVAM is strongly committed to the development and dissemination of AOPs and is 
part of the OECD AOP training group. 
During the reporting period EURL ECVAM has given four AOP training courses for the 
European Food Safety Authority (EFSA), for both EFSA staff and external experts at 
EFSA premises in Parma, Italy (via a Service Level Agreement); these four courses were 
held in September and November 2015 and in March and June 2016. In total, there were 
99 participants, i.e. an average of 25 per course. 
The courses aimed at creating awareness of the AOP framework, the principles and 
practices underlying AOP development, description, and evaluation, and to provide the 
participants with the theory and hands-on skills to facilitate use and application of AOPs. 
Course facilitators were EURL ECVAM staff together with (varying) external experts from 
the US (EPA and University of St. Thomas in St. Paul, Minnesota) and Canada (University 
of Ottawa).  
Besides lectures, one or two case studies were dealt with in four or five break out 
groups. In addition, an interactive exercise showed how AOPs can provide input for 
Integrated Approaches to Testing and Assessment (IATA) building. Besides plenary 
discussions, a final brainstorming on how AOP thinking could be incorporated into daily 
work was held.  
Experience and feedback from each course was integrated in the preparation of the 
following course and also shared with the OECD training group. 
6.6 Update on the EURL ECVAM Genotoxicity and Carcinogenicity 
Database of Ames Positive Chemicals  
The EURL ECVAM Genotoxicity and Carcinogenicity Consolidated Database of Ames 
positive chemicals, launched at the end of 2014, is a structured database compiling 
available genotoxicity and carcinogenicity data for 726 Ames positive chemicals 
originating from different sources (Kirkland et al., 2014a). 
It was constructed following a recommendation of an EURL ECVAM Workshop on “Can in 
vitro mammalian cell genotoxicity test results be used to complement positive results in 
the Ames test and help predict carcinogenic or in vivo genotoxic activity?” (Kirkland et 
al., 2014a). Its development, was one of the main objective of the published EURL 
ECVAM strategy to Avoid and Reduce Animal Use in Genotoxicity Testing" (Corvi et al., 
2013).  
By using a harmonised format to gather the information, this database is representing a 
powerful resource for data analysis that is meant to be used to guide a thorough 
evaluation of genotoxicity and carcinogenicity as a resource for evaluating the 
predictivity of the Ames test for in vivo genotoxicity and carcinogenicity when considered 
alone or in association with in vitro mammalian cell assays (gene mutation and 
clastogenicity/aneugenicity) and for a better characterisation of those cases where the 
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Ames test leads to irrelevant ('false positive') results. In addition, it is used as a platform 
for detailed structural characterisation of specific groups of compounds with or without 
carcinogenic or genotoxic activity. Inconsistencies (e.g. contradictory data derived from 
different sources) and poor data quality have been addressed through rigorous curation 
which included expert peer review.  
Since its launch, the Genotoxicity & Carcinogenicity Database has become a reference 
database for the regulatory and scientific community as demonstrated by a number of 
activities carried out recently:  
• The database and the subsequent analysis of Ames positive chemicals contributed 
to the 9th revision of SCCS's Notes of Guidance for testing cosmetic ingredients and 
their safety evaluation in the area of mutagenicity and genotoxicity (SCCS, 2015); 
• The database has been considered the starting point for a huge project launched 
by the CEFIC Long-Range Research Initiative (LRI-B18);  
• It is contributing to an on-going activity on in vivo follow up studies of the 
Genetic Toxicology Technical Committee of ILSI/HESI;  
• It has been used to investigate the performance of an integrated approach to 
testing and assessment (IATA) designed to cover different genotoxic mechanisms 
causing cancer (Petkov et al., 2016). 
The database has been linked to two other JRC databases, ChEList (see 6.7) and 
ChemAgora (see 6.8) and, in the past year, to information published in the updated 
recommended list of genotoxic and non-genotoxic chemicals (Kirkland et al, 2016). This 
allows the retrieval of additional information on the chemicals of interest using a single 
platform. 
The database is meant as a living project with possibilities of update as new genotoxicity 
and carcinogenicity data are made available. In fact, an extension of the database is 
currently on-going to include chemicals with Ames negative results.  
6.7 Update on CheLIST  
A key requirement for the development, characterisation and eventual validation of 
alternative (non-animal) methods for use in biomedical research and regulatory safety 
assessment is the availability of suitable reference or benchmark chemicals for which 
reliable structural, physicochemical and biological property data are available. However, 
the type of information needed to select such reference chemicals is typically scattered 
across a plethora of heterogeneous databases, project websites and peer-reviewed 
literature. To tackle this issue, EURL ECVAM has published the "Chemical Lists 
Information System" (CheLIST) that provides a means of identifying whether a chemical 
(or chemical group) has been tested in a major EU or international research project and 
whether the chemical appears on a specific regulatory inventory. Information is provided 
on chemical identifiers (e.g. name, CAS number) and chemical structure, and the 
database can be searched according to these types of information. The various datasets 
and inventories can also be compared in order to identify overlaps in chemical 
membership and to generate customised lists. All lists can be downloaded and the 
references provided for each list allow traceability back to the source. 
Using CheLIST, alternative methods can be developed faster as information about 
reference chemicals (for method validation) is available more easily. 
In the reporting period CheLIST continued to grow, with EURL ECVAM monitoring the 
chemical programme landscape to identify more lists to add to CheLIST. 
6.8 Update on ChemAgora 
People in need of a comprehensive overview of what information is available about a 
certain chemical often struggle with the heterogeneity of that information, scattered 
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across numerous locations, in different formats and stored under often conflicting 
identifiers. 
ChemAgora, the chemical information portal maintained by EURL ECVAM, facilitates the 
online retrieval of available information on a certain chemical substance. Chemicals can 
be searched by their name (or parts of it), CAS Registry number, InChIKey or chemical 
structure in a series of public repositories. Hyperlinks to the exact third party pages are 
provided, where more information about the chemical can be found. The tool also 
provides a list of synonyms the chemical is known under. Using ChemAgora, third party 
databases can be searched by an identifier originally not available in these repositories. 
Thus, ChemAgora is not only useful for getting an overview of what is currently known 
about a substance, but also adds value to third party systems. 
Making access to information about chemical substances easier across heterogeneous 
platforms raises the public awareness about chemical knowledge. Stakeholders in the 
chemical community can take more informed decisions when being fully aware of the 
information available about a certain substance, and people using ChemAgora have a 
head start when it comes to finding out many details about a chemical. 
In the reporting period ChemAgora continued to grow, with EURL ECVAM monitoring the 
chemical DB landscape to identify more databases to be searched via ChemAgora. 
6.9 The Endocrine Active Substances Information System (EASIS) 
The endocrine system is very complex, affecting many organs and regulating numerous 
biological processes (such as development, growth, reproduction, metabolism, immunity 
and behaviour). Hormones (synthesised by the endocrine system) act in very small 
amounts and at precise moments in time. Chemicals that interfere with the endocrine 
system can potentially have adverse effects on both humans and wildlife.  
"An endocrine disruptor is an exogenous substance or mixture that alters function(s) of 
the endocrine system and consequently causes adverse health effects in an intact 
organism, or its progeny, or (sub)populations" (IPCS/WHO, 2002). 
The term "endocrine active substance" (EAS) is used to describe any chemical that can 
interact directly or in-directly with the endocrine system, and subsequently result in an 
effect on the endocrine system, target organs and tissues. Whether the effect is adverse 
(“disruptive”) or not will depend on the type of effect, the dose and the background of 
the physiological situation (EFSA, 2010). 
EASIS, the Endocrine Active Substances Information System, is a web-based application 
open to the public for query and review of results from scientific studies on chemicals 
related to endocrine activity or adverse effects (considered in relation to an endocrine 
disrupting mode of action). It deals generally with Endocrine Active Substances, i.e. not 
only with Endocrine Disruptors. 
The starting point of EASIS was a database created by the European Commission's 
Environment Directorate-General (DG ENV) in 2006. A new application, EASIS, was 
developed and the data from the DG ENV database were migrated into EASIS. More data 
to cover the period after 2006 were added. There are currently data from around 9000 
studies across 513 compounds in EASIS (see table 6.2).  
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Table 6.2 Compounds and Studies in EASIS 
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Table 6.2 shows the four study types into which EASIS data are divided. The total 
number of compounds is higher than 513 due to multiple study types per compound. 
EASIS has recently been made available to the public. 
6.10 Dissemination and training activities of EPAA   
In the framework of its collaboration with the Institute for In vitro Sciences (IIVS), the 
European Partnership for Alternative Approaches to Animal Testing (EPAA) supported the 
production of a 13-minutes video that demonstrates how to perform the BCOP (Bovine 
Corneal Opacity and Permeability) assay according to OECD TG 437. The video focuses 
on steps that are critical to the success of the assay such as handling of the isolated 
cornea and removal of the test material from the cornea at the conclusion of the 
exposure time. The video is available in an English version as well as two subtitled 
versions (Chinese, Portuguese) free of charge on the EPAA website69 and on YouTube70.  
In the framework of the EPAA/IIVS collaboration, a second educational training video on 
the 3T3 Neutral Red Uptake Phototoxicity test has been produced. It shows how to 
perform the assay as described in the OECD TG no. 432. The video is available online in 
an English version 71  as well as two subtitled versions, notably Portuguese 72  and 
Chinese73. 
Other dissemination activities of EPAA in the reporting period comprised the co-
organisation of scientific workshops on clostridial vaccines74 (see 5.9.4) and biologicals75 
(see 5.9.6). 
6.11 European Citizens' Initiative Action 1: Accelerating progress 
in the Three Rs through knowledge sharing 
In the context of the European Commission's Communication (Action 1)76, published in 
response to the European Citizens' Initiative "Stop Vivisection" 77 , EURL ECVAM 
conducted a public survey to solicit input from individuals (based on personal 
experience) and organisations, regarding i) the availability of knowledge sources for 
their activities with potential relevance to Replace, Reduce or Refine (the 'Three Rs') the 
use of animals for scientific purposes, ii) to understand how such knowledge is currently 
used, disseminated or shared, and iii) to highlight opportunities which could fill apparent 
knowledge gaps and enhance knowledge sharing. The survey was widely disseminated 
by stakeholders and scientific networks and 351 responses were received. These replies 
included individual responses as well as 36% who replied on behalf of their organisations 
(some of which employ over 1000 people).  
The results of this survey were fed into a comprehensive, systematic study currently 
being undertaken by the Commission to map data, information and knowledge resources 
of different types which are readily available in the public domain in the different 
scientific fields and industry sectors. The study addresses those that could be exploited 
to replace animal studies with alternative approaches not involving animals, to adapt 
                                           
69 https://ec.europa.eu/growth/sectors/chemicals/epaa/project-platform_en  
70 https://www.youtube.com/playlist?list=PLLt7eTk-UdPiH0jWO16YfIwnp-gmeb5Uo  
71 https://vimeo.com/156328249 
72 https://vimeo.com/175576942 
73 https://vimeo.com/175590221 
74 EPAA-EDQM workshop: Clostridial Vaccines workshop BSP 130, Egmond Aan Zee, the 
Netherlands, 15-16 September 2015 
75  EPAA Workshop: Modern science for better quality control of medicinal products 
'Towards global harmonization of 3Rs in biologicals, Egmond Aan Zee, the Netherlands, 
15-16 September 2015 
76 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/vivisection/en.pdf  
77 http://ec.europa.eu/citizensinitiative/public/initiatives/successful/details/2012/000007  
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studies to reduce the number of animals needed, or to refine studies so as to minimise 
pain, suffering and distress of the animal, and to improve its welfare. Moreover, the 
study aims to explore how sharing of knowhow and access to resources could be 
enhanced to accelerate overall progress in the Three Rs in every domain where animals 
are used for a scientific purpose, whether it be for basic biological research, toxicological 
testing, or for training and education. The outcome of the study, together with the 
survey results, will be made public by the end of 2016 and presented in December 2016 
at a European Commission scientific conference, Non-Animal Approaches - The Way 
Forward78, to engage the scientific community and relevant stakeholders in a debate on 
how to accelerate progress in the Three Rs. 
7 International Cooperation on Alternative Test Methods 
(ICATM)  
ICATM Meeting 2015 
The meeting of the International Cooperation on Alternative Test Methods (ICATM) 
partners was held on 10th – 11th November 2015 at the JRC in Ispra. Alongside EURL 
ECVAM, ICATM includes the US Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM), the Japanese Center for the Validation of Alternative 
Methods (JaCVAM), the Korean Centre for the Validation of Alternative Methods 
(KoCVAM) and Health Canada (HC). China and Brazil participated as observers at this 
meeting, represented by the National Institutes for Food and Drug Control (NIFDC) and 
the Brazilian Centre for the Validation of Alternative Methods (BraCVAM), respectively.  
A workshop on the international regulatory applicability and acceptance of alternative 
non-animal approaches to skin sensitisation assessment of chemicals used in a variety of 
sectors will take place from 4th to 5th October 2016. Regulators from each of the ICATM 
partners' jurisdictions will also participate. The aim of this workshop is to facilitate a 
common understanding of the non-animal approaches which are available and their 
current proposed use, particularly within defined approaches and IATA. It will also seek 
to determine what still needs to be done in this area in order to establish general criteria 
for the evaluation and acceptance of IATA. Another goal will be to identify the obstacles 
that hamper the use of non-animal approaches in certain regulatory areas and regions 
by chemical sector and clearly define what steps should be taken to support their 
regulatory application.  
 
 
 
8 EURL ECVAM strategies 
8.1 Follow-up to the EURL ECVAM Strategy for Achieving 3Rs 
Impact in the Assessment of Toxicokinetics and Systemic 
Toxicity  
The EURL ECVAM Toxicokinetics (TK) Strategy79 was set up to promote a better use of 
TK data in chemical safety assessment while respecting the Three Rs. It is centred 
around four strategic aims:  
                                           
78  http://www.euconf.eu/non-animal-approaches-the-way-forward/en/registration/index. 
html  
79  https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-publishes-its-strategy-in-the-area-of-
toxicokinetics 
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(1) Development of standards for human in vitro absorption, distribution, metabolism 
and excretion (ADME) methods. There is growing awareness that Toxicokinetic (TK) data 
are an indispensable information source for human chemical risk assessment and trigger 
the need to develop in vitro methods to obtain TK information. This includes, for 
example, the in vitro characterisation of metabolism to identify key metabolic routes or 
to estimate clearance as a surrogate for in vivo metabolism. Hepatic metabolic clearance 
is an important factor in toxicokinetics; therefore many in vitro clearance methods have 
been developed and are already in use. There is the need to standardise the way these 
methods are described and characterised to increase their reliability and relevance when 
used to inform risk assessment-decision making. With respect to this, EURL ECVAM is 
currently defining harmonised descriptive standards for characterising in vitro methods 
as guidance to measure human in vitro hepatic metabolic clearance and to facilitate 
method comparison. This work is following up on the collective knowledge-gathering 
exercise (involving literature survey, test submission e-survey and an expert workshop) 
carried out from 2013 to 2015 (see 3.10 of EURL ECVAM status report 2015, Zuang V. et 
al., 2015).  
(2) Good modelling practice: So far a number of biokinetic models (such as 
physiologically based kinetic (PBK) models) have enabled the investigation of potential 
TK interactions and facilitate the incorporation of TK data in risk assessment (i.e 
applying IVIVE). The foundation of good modelling practice is based on harmonised 
understanding (terminology/definition) and good knowledge as well as on the relevance 
and reliability of available input data. The needs and challenges now are in building and 
reporting of an animal-free PBK modelling and how such a model would then be 
validated. To achieve international consensus a workshop entitled: “Physiologically-
based kinetic modelling in risk assessment–Reaching a whole new level in regulatory 
decision-making” will be held at JRC, EURL ECVAM in November 2016. 
(3) Data collection: An ongoing collection of already existing databases reporting on 
chemical parameters, in vitro data and/or in silico predictions, is currently being 
performed. This information will be used for the development of kinetic modelling. 
(4) Regulatory anchoring: Current efforts are on the development of a guidance on 
hepatic clearance and on good modelling practice of PBK models. This will give insight 
into the acceptance of these methods and on how to generate and use ADME/TK data in 
a regulatory setting for better risk assessment processes for both exposure and co- 
exposure of single chemicals or mixture.  
Implementation of the strategy is the way forward for increasing the development, 
harmonisation and acceptance of human TK data in several areas of toxicology.  
 
8.2 Implementing the EURL ECVAM Strategy to Avoid and Reduce 
Animal use in Genotoxicity Testing  
A strategic plan to avoid and reduce animal use in genotoxicity testing had previously 
been described by EURL ECVAM, based on the regulatory requirements across different 
EU legislations, state of the science, and latest and ongoing efforts undertaken by 
various organisations, including EURL ECVAM (ECVAM, 2013). It was proposed that in 
the short- and medium-term efforts should be directed towards the overall improvement 
of the current testing strategy for better hazard assessment with the use of fewer or no 
animals to satisfy the information requirements of various EU legislations. In recent 
years several activities have taken place to address one of the main strategic aims, 
which focused at enhancing the performance of the in vitro testing battery to reduce the 
need for in vivo follow-up tests. These activities and the related achievements have been 
summarised by Corvi and Madia (2016). They include the improvement of existing tests, 
the development of novel tests, as well as, the establishment and exploration of 
approaches to optimise in vitro testing accuracy. Furthermore useful tools, such as 
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databases of reference chemical lists have been developed to support advance in the 
field.  
 
9 Conclusions 
Research and development activities continued to be funded during 2016 for the 
complex endpoints such as repeated dose and reproductive toxicology, where the 
toxicological processes and the mechanistic understanding have not been sufficiently 
elucidated yet and for which Three Rs solutions are more difficult to find. These projects 
focus on the integration of in vitro non-animal methods and in silico computational 
technologies to translate molecular mechanistic understanding of toxicity into safety 
testing strategies. Several R&D projects are also ongoing for fish toxicity and 
bioaccumulation testing ranging from the use of a fish cell line-based cytotoxicity assay 
for acute fish toxicity testing over the development of AOPs for chronic fish toxicity 
testing and of a tiered testing strategy based on in vitro approaches for fish 
bioaccumulation testing, to the application of threshold of toxicological concern in 
aquatic toxicity assessment. 
For the quality control of vaccines, research projects aim to develop, optimise and 
evaluate non-animal methods for routine batch quality, safety and efficacy testing of 
vaccines.  
Good progress in the validation and regulatory acceptance is made in areas where non-
animal alternative methods have been developed and validated and where the focus lies 
in an intelligent combination/ integration of the various non-animal approaches. This has 
been achieved in the areas of topical toxicity and skin sensitisation. In the latter area, 
several OECD test guidelines have recently been adopted and Guidance Documents have 
been prepared. These GDs aim to provide a set of principles for the proper reporting of 
defined approaches to testing and assessment and the related reporting templates in 
order to facilitate their regulatory use. The GDs also show how the reporting templates 
have been used to document a number of defined approaches developed in that area. In 
the area of genotoxicity, efforts have been made on the overall improvement of the 
current testing strategy for better hazard assessment with the use of fewer or no 
animals to satisfy the information requirements of various EU legislation. Since 
toxicokinetic (TK) data are crucial for human chemical risk assessment, efforts are 
currently focused on the development of standards for human in vitro absorption, 
distribution, metabolism and excretion (ADME) methods and on good modelling practice. 
EURL ECVAM intensified its discussions with regulators and stakeholders on the latest 
developments in the field such as e.g. the validation and regulatory use of IATAs and 
continues to explore the possible regulatory use of alternative (non-animal) approaches 
to systemic toxicity that are intended for the hazard and safety assessment of chemicals 
also in international fora. 
Information on alternatives has been disseminated through a variety of dedicated 
meetings, training efforts and specialised database services.  
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Annex I – Summary status of the adoption of Test Guidelines based on alternative methods in 
the OECD TG programme (2012-2016)  
Table 1 summarises the status of adoption of OECD test guidelines on alternative methods from 2012 to 2016. It should be noted that 
beside TGs, also Guidance Documents and new projects on alternative methods were respectively adopted and included on the OECD 
Work programme during that period. For additional information, please consult the OECD website of the Test Guideline Programme: 
http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm 
Table 1. Status of adoption of OECD Test Guidelines based on alternative methods 2012-2016 
Nr. Toxicity area Test method description Acceptance status 
1 Skin corrosion Reconstructed human Epidermis (RhE) test 
methods as included in OECD TG 431/EU TM B.40 
bis 
Adopted in 2004; updated version (sub-categorisation, 
inclusion of performance standards, inclusion of 
SkinEthic™ RHE and epiCS®) adopted in 2013. 
Revised version including sub-categorisation with the 
epiCS® test method adopted in 2014. 
Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on 
Testing and Assessment No. 219), inclusion of 
paragraphs referring to the IATA for Skin Corrosion 
and Irritation (OECD GD No. 203) and inclusion of the 
use of HPLC/UPLC-spectrophotometry as an alternative 
procedure to measure tissue viability (increasing the 
applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-
formazan). 
Updated in 2016 for improving the prediction models of 
EpiDermTM, SkinEthicTM RHE and epiCS®) for a more 
accurate prediction of Sub-Categories 1A and 1B-and-
1C combined 
2 Skin corrosion Transcutaneous Electrical Resistance (TER) test 
method as included in OECD TG 430/EU TM B.40 
Adopted in 2004; updated version (inclusion of 
performance standards) adopted in 2013 
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Nr. Toxicity area Test method description Acceptance status 
 Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on 
Testing and Assessment No. 218) and the inclusion of 
paragraphs referring to the IATA for Skin Corrosion 
and Irritation (OECD GD No. 203) 
3 Skin corrosion In vitro Membrane Barrier Test Method for Skin 
Corrosion as included in OECD TG 435/EU TM B.40 
 
Adopted in 2006; Updated in 2015 for the inclusion of 
the Corrositex® prediction model, the deletion of the 
performance standards (to be published separately on 
the Series on Testing and Assessment), the inclusion of 
paragraphs referring to the IATA for Skin Corrosion 
and Irritation and the updating of the list of proficiency 
substances (OECD GD No. 203) 
4 Skin irritation Reconstructed human Epidermis (RhE) test 
methods as included in OECD TG 439/EU B.46 
Adopted in 2010; updated version (inclusion of 
LabCyte EPI-model24 SIT) adopted in 2013 
Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on 
Testing and Assessment No. 220), inclusion of 
paragraphs referring to the IATA for Skin Corrosion 
and Irritation (OECD GD No. 203) and inclusion of the 
use of HPLC/UPLC-spectrophotometry as an alternative 
procedure to measure tissue viability (increasing the 
applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-
formazan) 
5 Serious eye 
damage/eye 
irritation  
Fluorescein Leakage (FL) test method as included 
in OECD TG 460 
Adopted in 2012 
6 Serious eye 
damage/eye 
Bovine Corneal Opacity and Permeability (BCOP) 
test method as included in OECD TG 437/EU TM 
Adopted in 2009; updated version (revision of positive 
controls, use to identify non-classified chemicals and 
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Nr. Toxicity area Test method description Acceptance status 
irritation B.47 several other revisions) adopted in 2013 
7 Serious eye 
damage/eye 
irritation 
Isolated Chicken Eye (ICE) test method as 
included in OECD TG 438/EU TM B.48 
Adopted in 2009, updated version (use to identify non-
classified chemicals and several other revisions) 
adopted in 2013 
8 Serious eye 
damage/eye 
irritation 
Cytosensor Microphysiometer (CM) test method New draft TG first discussed at WNT in 2013 but not 
adopted, pending further clarification on its use to 
identify non-classified chemicals. The additional data 
requested by the WNT that should have been 
submitted by US to support the project were not 
received and thus the project has been discontinued 
because of lower priority for the EC 
9 Serious eye 
damage/eye 
irritation 
Short Time Exposure (STE) test method for the 
detection of chemicals causing serious eye 
damage and chemicals not requiring classification 
for serious eye damage or eye irritation, as 
included in OECD TG 491 
Adopted as a new TG in 2015 
10 Serious eye 
damage/eye 
irritation 
Reconstructed human Cornea-like Epithelium 
(RhCE) for the detection of chemicals not 
requiring classification and labelling for eye 
irritation or serious eye damage as included in 
OECD TG 492 
Adopted as a new TG in 2015 
11 Skin sensitisation In chemico skin sensitisation: Direct Peptide 
Reactivity Assay (DPRA), as included in OECD TG 
442C 
Adopted as a new TG in 2015 
12 Skin sensitisation In vitro skin sensitisation: ARE-Nrf2 Luciferase 
test method (KeratinoSens™), as included in 
OECD TG 442D 
Adopted as a new TG in 2015 
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Nr. Toxicity area Test method description Acceptance status 
13 Skin sensitisation In vitro Skin Sensitisation Test: Human Cell Line 
Activation Test (h-CLAT), as included in OECD TG 
442E 
Adopted as a new TG in 2016. 
14 Carcinogenicity In vitro Syrian Hamster Embryo (SHE) Cell 
Transformation Assay (CTA) as included in OECD 
GD no 214* 
Adopted as a new GD in 2015 
15 Carcinogenicity In vitro Bhas 42 Cell Transformation Assay (CTA) 
as included in OECD GD no 231* 
Adoption as a new GD in 2016 
 
16 Genotoxicity In vitro Mammalian Chromosome Aberration 
Assay as included in OECD TG 473 
 
 
Updated OECD TG 473 (originally adopted in 1983) 
adopted in 2014. Updated in 2016 to reference the 
Guidance Document on genetic toxicology Test 
Guidelines 
17 Genotoxicity In vitro Mammalian Cell Micronucleus Assay as 
included in OECD TG 487  
Updated OECD TG 487 (originally adopted in 2010) 
adopted in 2014. Updated in 2016 to reference the 
Guidance Document on genetic toxicology Test 
Guidelines  
18 Genotoxicity In vitro Mammalian Cell Gene Mutation Test using 
Hprt and xprt genes as included in OECD TG 476  
 
 
OECD TG 476 (originally adopted in 1984) "In vitro 
Mammalian Cell Gene Mutation Test" has been split up 
into two TGs:  
1. The updated TG 476 now using the Hprt and xprt 
genes was adopted in 2015; 
2. OECD TG 490 using Thymidine Kinase Gene was 
adopted in 2015. Both TGs were updated in 2016 to 
reference the Guidance Document on genetic 
toxicology Test Guidelines and TG 490 was also 
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Nr. Toxicity area Test method description Acceptance status 
corrected (see below) 
19 Genotoxicity In vitro Mammalian Cell Gene Mutation Tests 
Using the Thymidine Kinase Gene as included in 
OECD TG 490 
Adopted as TG 490 in 2015 (see above). Updated in 
2016 to reference the Guidance Document on genetic 
toxicology Test Guidelines and to correct a paragraph 
related to the maximum concentration that is based on 
cytotoxicity  
20 Endocrine 
disruption 
Estrogen receptor transactivation assay (BG1Luc 
ER TA; agonist and antagonist protocols) as 
included in OECD TG 457 
Adopted in 2012 
OECD TG 457 was deleted in 2015.  The method was 
included in OECD TG 455 in 2012 (agonist part) and 
2015 (antagonist part) (see table entry below) 
21 Endocrine 
disruption 
Performance-Based Test Guideline for Stably 
Transfected Transactivation In Vitro Assays to 
Detect Estrogen Receptor Agonists and 
Antagonists 
OECD 455 adopted in 2009 (STTA assay using the 
hERα-HeLa-9903 cell line); updated version (PBTG, 
inclusion of BG1Luc ER TA assay using the BG1Luc-4E2 
cell line) adopted in 2012; Second updated version, 
including  the antagonist part of both methods was 
adopted in 2015. 
This update led to the deletion of OECD TG 457 in 
parallel as it is no longer needed (see above). 
Third updated version to include the ER-CALUX method 
was approved in 2016 
22 Endocrine 
disruption 
Performance-Based Test Guideline for Human 
Recombinant Estrogen Receptor (hrER) In Vitro 
Assays to Detect Chemicals with ER Binding 
Affinity as included in OECD TG 493 
Adopted as new TG in 2015. It includes two reference 
test methods: 
 In Vitro Estrogen Receptor (ER) Binding Assay 
Using a Full Length Human Recombinant ERα; 
 In Vitro Estrogen Receptor Binding Assay Using a 
Human Recombinant Ligand Binding Domain 
Protein 
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Nr. Toxicity area Test method description Acceptance status 
23 Endocrine 
disruption 
Stably Transfected Human Androgen Receptor 
Transcriptional Activation Assay for Detection of 
Androgenic Agonist and Antagonist Activity as 
included in OECD TG 458 
Adopted as new TG in 2016 
24 Acute  fish 
toxicity  
Fish Embryo Acute Toxicity (FET) Test as included 
in OECD TG 236 
Adopted in 2013 
 
* These test methods were initially proposed to be included in Test Guidelines. It was later decided to include them in Guidance 
Documents. 
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Annex II – ICATM Alternative Test Methods Validation and Status of Regulatory Acceptance 
Table 2. ICATM Alternative Test Methods Validation and Status of Regulatory Acceptance 
Method Current Status Lead Action 
Organisation 
International Acceptance 
Dermal Corrosivity Test Methods 
CORROSITEX Skin Corrosivity 
Test 
Completed  OECD TG 435 (2006) 
Updated version (including the 
Corrositex® prediction model, the 
deletion of the performance 
standards (to be published 
separately in the Series on Testing 
and Assessment), including 
paragraphs referring to the IATA 
for Skin Corrosion and Irritation in 
OECD GD No. 203 and the 
updating of the list of proficiency 
substances) adopted in 2015 
EpiSkin™, EpiDerm™, SkinEthic™, 
epiCS® Skin Corrosivity Tests 
Completed  OECD TG 431 (2004), updated 
version (sub-categorisation, 
inclusion of performance 
standards, inclusion of SkinEthic™ 
RHE and epiCS™) adopted in 2013. 
Revised version including the sub-
categorization with the epiCS™ 
test method adopted in 2014 
Updated version [deleting the 
performance standards (published 
separately in the Series on Testing 
and Assessment No. 219), 
including paragraphs referring to 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
the IATA for Skin Corrosion and 
Irritation in OECD GD No. 203 and 
including the use of HPLC/UPLC-
spectrophotometry as an 
alternative procedure to measure 
tissue viability (increasing the 
applicability domain of the test 
methods to coloured substances 
interfering with the measurement 
of MTT-formazan)] adopted in 
2015. Updated in 2016 for 
improving the prediction models of 
EpiDermTM, SkinEthicTM RHE and 
epiCS®) for a more accurate 
prediction of Sub-Categories 1A 
and 1B-and-1C combined. 
Rat TER Skin Corrosivity Test Completed  OECD TG 430 (2004), updated 
version (inclusion of performance 
standards) adopted in 2013 
Updated version (deleting the 
performance standards (published 
separately in the Series on Testing 
and Assessment No. 218) and 
including paragraphs referring to 
the IATA for Skin Corrosion and 
Irritation in OECD GD No. 203) 
adopted in 2015 
Dermal Irritation Test Methods 
In vitro reconstructed human 
epidermis (RhE) test methods: 
Completed  OECD TG 439 (2010),  updated 
version (including the LabCyte™ 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
EpiDerm™, EpiSkin™, SkinEthic™ 
RHE and LabCyte EPI-MODEL24 
SIT  
 EPI-model) adopted in 2013 
Updated version [deleting the 
performance standards (published 
separately in the Series on Testing 
and Assessment No. 220, including 
paragraphs referring to the IATA 
for Skin Corrosion and Irritation in 
OECD GD No. 203 and including 
the use of HPLC/UPLC-
spectrophotometry as an 
alternative procedure to measure 
tissue viability (increasing the 
applicability domain of the test 
methods to coloured substances 
interfering with the measurement 
of MTT-formazan)] adopted in 
2015 
In vitro reconstructed human 
epidermis (RhE) test methods: 
Korean epidermis model 
KoCVAM sponsored validation 
study is ongoing 
KoCVAM  
Phototoxicity Test Methods 
3T3 NRU Phototoxicity Test Completed  OECD TG 432 (2004) 
ICH S10 (2014) 
Test method battery to predict 
phototoxicity (yeast growth inhibition 
phototoxicity assay and red blood 
cell photohemolysis assay) 
Japanese Regulatory Acceptance 
Board recommended additional 
work be performed 
JaCVAM  
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Method Current Status Lead Action 
Organisation 
International Acceptance 
In vitro test method based on 
reactive oxygen species (ROS) 
and photostability  
Completed  ICH S10 (2014) 
SPSF to develop an OECD TG was 
approved in 2016 
Ocular Toxicity Test Methods 
Bovine Corneal Opacity and 
Permeability (BCOP) Test Method 
Completed  OECD TG 437 (2009), updated 
version (positive control, use in a 
bottom-up approach to identify 
non-classified chemicals and 
several other revisions) adopted in 
2013 
Isolated Chicken Eye (ICE) Test 
Method 
Completed  OECD TG 438 (2009), updated 
version (use in a bottom-up 
approach to identify non-classified 
chemicals and several other 
revisions) adopted at WNT in 2013 
Use of Histopathology as an 
additional endpoint in Ocular 
Safety Testing 
Completed  OECD GD 160 (2011) 
Cytotoxicity test: SIRC CVS Peer review coordinated by 
JaCVAM is ongoing 
JaCVAM; EURL ECVAM, 
ICCVAM, KoCVAM and 
Health Canada VMT 
 
Cytotoxicity test: three-dimensional 
dermal model (MATREX) 
JaCVAM-sponsored validation 
study in the planning stage 
JaCVAM   
Cytotoxicity test: Short Time 
Exposure (STE) test 
Completed  OECD TG 491 (2015) 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
Use of anaesthetics, analgesics, 
and humane endpoints for 
routine use in TG 405 
 
Completed  OECD updated TG 405 (2012b) 
In vitro approach for categorisation 
of anti-microbial cleaning products: 
recommendations for further studies 
Completed. EPA/OPP80 has 
concluded from submission and 
review of alternative eye irritation 
tests conducted on antimicrobial 
pesticide products with cleaning 
claims (AMCPs) that the proposed 
testing approach is acceptable for 
determining the appropriate eye 
hazard classification and labelling 
for AMCPs (see 
http://www.epa.gov/pesticides/reg
ulating/eye-policy.pdf for the 
details of the scope of the policy). 
ICCVAM  
Cytosensor Microphysiometer® (CM) 
Test method 
The draft TG was submitted to 
OECD for comments including a 
set of Performance Standards  
EURL ECVAM; ICCVAM New draft TG discussed at WNT in 
2013, 2015 and 2016 but not 
adopted. The additional data 
requested by the WNT that should 
have been submitted by US to 
support the project were not 
received and thus the project has 
been discontinued because of lower 
priority for the EC. 
                                           
80 Environmental Protection Agency/Office of Pesticide Program  
 63 
 
Method Current Status Lead Action 
Organisation 
International Acceptance 
Fluorescein Leakage (FL) test 
method 
Completed  OECD TG 460 (2012) 
Human reconstructed tissue 
models for eye irritation 
EpiOcular™ EIT 
Completed  OECD TG 492 (2015) 
 
 
Vitrigel-EIT Peer review coordinated by 
JaCVAM is ongoing 
JaCVAM; EURL ECVAM, 
NICEATM, ICCVAM, 
Health Canada and 
KoCVAM VMT liaisons 
 
Human reconstructed tissue models 
for eye irritation 
LabCyte Cornea-model 
Peer review coordinated by 
JaCVAM is ongoing 
JaCVAM; and Korean 
expert VMT liaisons 
 
OptiSafe Validation Study coordinated by 
NICEATM is currently in Phase 1 
NICEATM; ICCVAM and 
EURL ECVAM VMT 
liaison 
 
In vitro reconstructed human 
Cornea-epithelium model (RhCE) test 
method: Korean Cornea-model 
KoCVAM-sponsored validation 
study started in 2016 
KoCVAM  
Hen's Egg Test-Chorioallantoic 
Membrane (HET-CAM) Test Method  
Validation study sponsored by 
Brazilian Ministry of Science, 
Technology Innovation and 
Communication (MCTIC). 
Preliminary phase of validation 
study ongoing 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
Immunotoxicity (Allergic Contact Dermatitis) Test Methods 
Murine local lymph node assay 
(LLNA) for skin sensitization 
 
Completed  OECD TG 429 (2002) 
ISO (2002) 
Updated Murine local lymph node 
assay (LLNA) for skin 
sensitization (20% reduction) 
 
Completed  Update to TG 429 OECD (2010) 
 
ISO (2010) 
Reduced LLNA (rLLNA) 
 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol 
(LLNA: BrdU-ELISA) 
Completed  OECD TG 442B OECD (2010) 
Nonradioactive LLNA protocol, 
LLNA:DA 
Completed   OECD TG 442A OECD (2010) 
Harmonized performance 
standards for the LLNA 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol (LLNA: 
BrdU-Flow Cytometry) 
KoCVAM validation study is on-
going 
KoCVAM SPSF to develop a TG approved in 
2016 
In vitro skin sensitisation assay 
(DPRA)  
Completed 
 
 OECD TG 442C (2015) 
 
In vitro skin sensitisation assay Completed EURL ECVAM; JaCVAM 
and ICCVAM VMT 
OECD TG 442E (2016) 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
(h-CLAT)  liaison members 
In vitro skin sensitisation assay 
KeratinoSens™ 
Completed   OECD TG 442D (2015) 
In vitro skin sensitisation assay 
IL-8 Luc assay 
Peer review coordinated by 
JaCVAM was completed 
JaCVAM; EURL ECVAM, 
NICEATM,, KoCVAM 
and Health Canada 
VMT liaisons 
SPSF to develop a TG approved in 
2015 
New draft TG discussed at OECD 
WNT meeting in 2016 
In vitro skin sensitisation assay 
Vitrigel-SST 
MAFF81-sponsored validation study 
is pending 
JaCVAM; EURL ECVAM, 
NICEATM, KoCVAM and 
Health Canada VMT 
liaisons 
 
In vitro skin sensitisation assay 
Amino acid derivative reactivity 
assay (ARDA) 
JCIA82 and JSAAE83 validation 
study is ongoing 
JaCVAM; NICEATM, EU 
experts and KoCVAM 
VMT liaisons 
 
IL-2 Luc assay for the evaluation of 
the immunotoxic potential of 
chemicals  
JaCVAM validation study is 
ongoing 
JaCVAM; NICEATM and 
EU experts VMT 
liaisons 
 
Electrophilic allergen screening assay 
(EASA) 
Validation study coordinated by 
NICEATM is currently being 
planned. Testing currently 
anticipated to begin Spring 2017. 
NICEATM; VMT 
currently being 
established from 
ICCVAM working group 
 
                                           
81 Ministry of Agriculture, Forestry and Fisheries 
82 Japan Cosmetic Industry Association 
83 Japanese Society for Alternatives to Animal Experiments 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
members and liaisons 
Acute Toxicity Test Methods 
Up and Down Procedure (UDP) Completed  OECD TG 425 (2008) 
In vitro cytotoxicity test methods 
for estimating starting doses for 
acute oral systemic toxicity tests 
Completed  
 
 OECD GD 129 (2010) 
In vitro cytotoxicity test (3T3 Neutral 
Red Uptake) for identifying 
substances with acute oral LD50 > 
2000 mg/kg b.w. 
 
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM 
Recommendation published in 
2013 
EURL ECVAM and 
ICATM organisations 
 
Zebrafish Embryo Toxicity test 
(ZFET) 
Completed   OECD TG 236 (2013) 
Toxicokinetic Test Methods 
In vitro hepatic biotransformation – 
CYP induction: Hepa RG and 
cryopreserved human hepatocytes 
 EURL ECVAM; 
NICEATM, and JaCVAM 
VMT liaisons 
SPSF for a PBTG approved in April 
2013. Draft PBTG underwent a first 
commenting round in 2014. An 
OECD expert meeting was held in 
March 2015.  
In vitro Fish Hepatic Metabolism - 
Two in vitro systems for deriving 
information on biotransformation and 
improving reliability of 
bioconcentration and 
Ring trial conducted under the 
auspices of the OECD  close to 
completion; ring trial report, draft 
test guidelines and draft guidance 
document in preparation; 1st WNT 
commenting round planned for 
United States and 
European Commission 
(through JRC-EURL 
ECVAM) 
SPSF for a TG on in vitro Fish 
Hepatic Metabolism approved in 
April 2014  
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Method Current Status Lead Action 
Organisation 
International Acceptance 
bioaccumulation factors (BCF & BAF) 
and avoiding use of fish bio-
concentration tests 
early 2017. 
Endocrine Disruptor Test Methods 
Stably transfected human 
estrogen receptor- 
transcriptional activation assay 
for detection of estrogenic 
agonist-activity of chemicals 
(STTA and BG1-Luc assays )  
Completed  OECD TG 455 (2009), updated 
2012 and 2015, inclusion of the 
antagonist protocols in addition to 
the agonist protocols, deletion of 
OECD TG 457 in parallel as it is no 
longer needed 
BG1Luc® human estrogen 
receptor transcriptional 
activation assay: agonist and 
antagonist protocols 
Completed  OECD TG 457 (2012) 
TG 457 has been deleted in parallel 
to TG 455 updates (see previous 
table entry) 
CertiChem MCF-7 cell proliferation 
assay for the detection of human 
estrogen receptor agonists and 
antagonists 
International validation study 
completed. Protocol must be 
revised for adequate 
transferability. 
NICEATM; EURL 
ECVAM, JaCVAM and 
KoCVAM VMT liaisons 
 
CertiChem MDA-Kb2 assay for the 
detection of human androgen 
receptor agonists and antagonists 
NICEATM coordinated single lab 
validation study ongoing 
NICEATM; ICCVAM and 
EURL ECVAM VMT 
liaison 
 
Stably transfected CHO Androgen 
receptor-α transcriptional 
activation assay for detection of 
androgenic agonist and 
antagonist activity of chemicals 
Completed JaCVAM and VMG NA 
liaisons 
OECD TG 458 (2016) 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
(AR-STTA) 
MELN® human estrogen receptor 
transcriptional activation assay: 
agonist and antagonist protocols 
Validation stopped   
Stably Transfected Transactivation in 
vitro Assay to detect Androgen 
Receptor Agonists and Antagonists 
Validation study ongoing  EURL ECVAM, NICEATM 
VMT, JaCVAM and 
KoCVAM VMT liaison 
SPSF to develop a PBTG on ARTA 
approved in April 2013 
Transactivation assay for the 
detection of compounds with 
(anti)androgenic potential using 
22Rv1/MMTV cells 
Validation study ongoing Ministry of Food and 
Drug Safety (MFDS) 
South Korea, EURL 
ECVAM and JACVAM 
VMT liaisons 
 
Performance-Based Test 
Guideline for Human 
Recombinant Estrogen Receptor 
(hrER) In Vitro Assays to Detect 
Chemicals with ER Binding 
Affinity 
Completed  OECD TG 493 
Genetic Toxicity Test Methods 
In vitro mammalian cell 
micronucleus test 
Completed  OECD TG 487 (2010), updated 
TG  adopted in 2014 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
In vitro mammalian cell 
chromosome aberration assay84 
Completed  OECD TG 473 (1997), updated 
TG  adopted in 2014 
In vivo comet assay Completed  OECD TG 489 (2014) 
In vitro comet assay Validation study for the in vitro 
comet assay stopped 
JaCVAM; EURL ECVAM, 
NICEATM and ICCVAM 
VMT liaisons 
 
Genotoxicity assays (micronucleus 
and comet) in 3D skin models 
Validation study ongoing Cosmetics Europe  
(lead); 
EURL ECVAM support 
 
Carcinogenicity Test Methods 
In vitro Bhas 42 cell 
transformation assay (CTA) 
Completed JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
OECD GD  231 (2016) 
In vitro Syrian hamster 
embryonic cells (SHE) cell 
transformation assays (CTAs) 
Completed  OECD GD 214 (2015) 
Reproductive Test Methods 
Hand-1 Luc assay METI85-sponsored validation is 
ongoing 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
 
                                           
84 The In vitro mammalian cell chromosome aberration assay has not been validated by any of the ICATM partners. It is added here for 
completeness as it has been adopted as an OECD TG 
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Method Current Status Lead Action 
Organisation 
International Acceptance 
 Health Canada, and 
KoCVAM VMT liaisons 
Quality Control testing of Biologicals 
Monocyte Activation Test (MAT) Collaborative Studies –  
1. Applicability of MAT to biological 
(hyperimmune sera and vaccines) 
2. MAT response to non-endotoxin 
pyrogens 
BraCVAM/INCQS and 
Renama 
Brazilian Pharmacopoeia 
Toxin Binding Inhibition (ToBI) test Collaborative Study - Applicability 
of ToBI for lot release - Tetanus 
Antitoxin for Human Use 
BraCVAM/INCQS and 
Renama 
Brazilian Pharmacopoeia 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                          
85 Ministry of Economy, Trade and Industry 
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